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A B S T R A C T
Background
Irritable bowel syndrome (IBS) is a prevalent condition that currently lacks highly eFective therapies for its management. Biofeedback has
been proposed as a therapy that may help individuals learn to exert conscious control over sympatho-vagal balance as an indirect method
of symptom management.
Objectives
Our primary objective was to assess the eFicacy and safety of biofeedback-based interventions for IBS in adults and children.
Search methods
We searched the Cochrane Inflammatory Bowel Disease (IBD) Group Specialized Trials Register, Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the Allied and
Complementary Medicine Database (AMED) from inception to 24 July 2019. We also searched reference lists from published trials, trial
registries, device manufacturers, conference proceedings, theses, and dissertations.
Selection criteria
We judged randomized controlled trials to be eligible for inclusion if they met the Association for Applied Psychophysiology and
Biofeedback definition of biofeedback, and if they compared a biofeedback intervention to an active, sham, or no-treatment control for
the management of IBS.
Data collection and analysis
Two authors independently screened trials for inclusion, extracted data, and assessed risk of bias. Primary outcomes were IBS global or
clinical improvement scores and overall quality of life measures. Secondary outcome measures were adverse events, assessments of stool
frequency and consistency, changes in abdominal pain, depression, and anxiety. For dichotomous outcomes, we calculated the risk ratio
(RR) and 95% confidence interval (CI). For continuous outcomes, we calculated the mean diFerence (MD) and 95% CI. We used GRADE
criteria to assess the overall certainty of the evidence.
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Main results
We identified eight randomized trials with a total of 300 adult participants for our analysis. We did not identify any trials in children. Four
trials assessed thermal biofeedback. One trial assessed rectosigmoidal biofeedback. Two trials assessed heart rate variability biofeedback.
Two trials assessed electrocutaneous biofeedback. Comparators were: no treatment (symptom monitoring group; three studies), attention
control (pseudomeditation; two studies), relaxation control (one study), counseling (two studies), hypnotherapy (one study), standard
therapy (one study), and sham biofeedback (one study). We judged all trials to have a high or unclear risk of bias.
Global/Clinical improvement
The clinical benefit of biofeedback plus standard therapy compared to standard therapy alone was uncertain (RR 4.20, 95% CI 1.40 to
12.58; 1 study, 20 participants; very low-certainty evidence). The same study also compared biofeedback plus standard therapy to sham
biofeedback plus standard therapy. The clinical benefit in the biofeedback group was uncertain (RR 2.33, 95% CI 1.13 to 4.80; 1 study, 20
participants; very low-certainty evidence).
The clinical benefit of heart rate biofeedback compared to hypnotherapy was uncertain when measured with the IBS severity scoring
system (IBS-SSS) (MD -58.80, 95% CI -109.11 to -8.49; 1 study, 61 participants; low-certainty evidence). Compared to counseling, the eFect
of heart rate biofeedback was unclear when measured with a composite symptom reduction score (MD 7.03, 95% CI -51.07 to 65.13; 1 study,
29 participants; low-certainty evidence) and when evaluated for clinical response (50% improvement) (RR 1.09, 95% CI 0.48 to 2.45; 1 study,
29 participants; low-certainty evidence).
The clinical benefit of thermal biofeedback used in a multi-component psychological intervention (MCPI) compared to no treatment was
uncertain when measured with a composite clinical symptom reduction score (MD 30.34, 95% CI 8.47 to 52.21; 3 studies, 101 participants;
very low-certainty evidence), and when evaluated as clinical response (50% improvement) (RR 2.12, 95% CI 1.24 to 3.62; 3 studies, 101
participants; very low-certainty evidence). Compared to attention control, the eFects of thermal biofeedback within an MCPI were unclear
when measured with a composite clinical symptom reduction score (MD 4.02, 95% CI -21.41 to 29.45; 2 studies, 80 participants; very low-
certainty evidence) and when evaluated as clinical response (50% improvement) (RR 1.10, 95% CI 0.72 to 1.69, 2 studies, 80 participants;
very low-certainty evidence).
Quality of life
A single trial used overall quality of life as an outcome measure, and reported that both the biofeedback and cognitive therapy groups
improved aMer treatment. The trial did not note any between-group diFerences, and did not report any outcome data.
Adverse events
Only one of the eight trials explicitly reported adverse events. This study reported no adverse events in either the biofeedback or cognitive
therapy groups (RD 0.00, 95% CI -0.12 to 0.12; 29 participants; low-certainty evidence).
Authors' conclusions
There is currently not enough evidence to assess whether biofeedback interventions are eFective for controlling symptoms of IBS. Given
the positive results reported in small trials to date, biofeedback deserves further study in people with IBS. Future research should include
active control groups that use high provider-participant interaction, in an attempt to balance non-specific eFects of interventions between
groups, and report both commonly used outcome measures (e.g. IBS-SSS) and historical outcome measures (e.g. the composite primary
symptom reduction (CPSR) score) to allow for meta-analysis with previous studies. Future studies should be explicit in their reporting of
adverse events.
P L A I N   L A N G U A G E   S U M M A R Y
Biofeedback for the treatment of irritable bowel syndrome
Review Question
We reviewed the evidence for the eFect of biofeedback therapy on the management of irritable bowel syndrome (IBS).
Background
IBS is a common disorder that includes both abdominal pain and changes in stool frequency or consistency. Biofeedback is a therapy
in which participants use technology to track a process that is not normally under conscious control (e.g. heart rate, tension of the anal
sphincter) in order to see how relaxed states of mind aFect these measures. Researchers have proposed that achieving more relaxed states
through the tool of biofeedback may help to improve the symptoms of IBS.
Study Characteristics
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We searched for studies that compared biofeedback to either no treatment, sham treatment, or to other active treatments for IBS. We
reviewed eight trials that included 300 total participants and assessed the eFect of biofeedback on IBS. Each of these studies only included
adults, and was carried out in an outpatient setting. The studies ranged from eight weeks to six months in length. The types of biofeedback
devices varied, and included heart rate variability, measures of skin temperature or electrical resistance, and the tension of the muscles
of the anus.
Study Funding Sources
None of the included trials disclosed funding sources.
Key Results
Our primary clinical outcomes were global clinical improvement and quality of life.
Regarding overall improvement, three trials compared biofeedback to no treatment and found that biofeedback as part of a relaxation
training program led to better symptom control than no treatment (very low-certainty evidence). Two of these trials also compared
biofeedback to an attention control and found minimal symptom improvement, but the eFects of chance could not be ruled out because
the evidence was of very low-certainty. One trial found a greater symptom benefit with heart rate biofeedback compared to hypnotherapy
(low-certainty evidence). Of two trials comparing biofeedback to counseling, any apparent eFect was minimal and the eFect of chance
could not be ruled out (very low-certainty evidence). When rectosigmoidal biofeedback was compared to relaxation control, the eFect
favored the relaxation control. The addition of biofeedback to standard medical therapy was superior to medical therapy alone and to
medical therapy plus sham biofeedback (low-certainty evidence for both findings).
Quality of Life
A single trial looked specifically at overall quality of life. Quality of life improved both for those in the biofeedback group and those in the
cognitive therapy group, but there was no overall diFerence between groups.
Adverse Events
Only one trial explicitly reported on adverse events. It reported no adverse events in either the biofeedback group or the cognitive therapy
group.
Certainty of the Evidence
We used the GRADE criteria to assess the certainty of the evidence for each of these findings. These ranged from low to very low.
The evidence is current up to July 2019.
Authors' Conclusions
We conclude that the existing data on biofeedback for IBS are limited and leave us uncertain about its value in IBS symptom management.
The studies currently available all have design limitations that make the results diFicult to apply to clinical settings. We do, however,
recommend further study in this area, as biofeedback could represent a unique approach for a diFicult to manage condition.
Biofeedback for treatment of irritable bowel syndrome (Review)











































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Biofeedback plus standard therapy compared to standard therapy for irritable bowel syndrome
Biofeedback plus standard therapy compared to standard therapy for irritable bowel syndrome
Patient or population: people with irritable bowel syndrome
Setting: outpatient setting
Intervention: biofeedback plus standard therapy
Comparison: standard therapy
Anticipated absolute effects* (95% CI)Outcomes



















(adequate improvement or remis-
sion)
follow-up: 6 months











Quality of life (QoL) No formal quality of life scales were used in the included trial. - - -  
Adverse events (AE) Adverse events were not reported in this study. - - -  
Serious adverse events (SAE) Serious adverse events were not reported in this study. - - -  
Abdominal pain (Pain)
assessed with: diaries
Scale from: 0 to 4
Lower score = better
Biofeedback plus standard therapy: mean pain scores reduced from 2.2 to 0.0 after
1 month and 0.6 after 6 months.











*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; RCT: randomized controlled trial; SD = standard deviation
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different





































































































































Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
aDowngraded one level for study limitations: lack of blinding and inadequately described protocols lead us to consider this a high risk of bias study.
b Downgraded two levels for imprecision: a single small study with a confidence interval that includes both a small and very large eFect of intervention.
c Downgraded one level for imprecision: CI not estimable.
d Downgraded an additional level for study limitations: measures of variation and statistical significance were not reported.
 
 
Summary of findings 2.   Biofeedback plus standard therapy compared to sham biofeedback plus standard therapy for irritable bowel syndrome
Biofeedback plus standard therapy compared to sham biofeedback plus standard therapy for irritable bowel syndrome
Patient or population: people with irritable bowel syndrome
Setting: outpatient setting
Intervention: biofeedback plus standard therapy
Comparison: sham biofeedback plus standard therapy
Anticipated absolute effects* (95% CI)Outcomes
Risk with sham biofeedback plus standard
therapy



















(adequate improvement or re-
mission)
follow-up: 6 months











Quality of life (QoL) No formal quality of life scales were used in the included trial. - - -  
Adverse events (AE) Adverse events were not reported in this study. - - -  
Serious adverse events (SAE) Serious adverse events were not reported in this study. - - -  
Abdominal pain (Pain)
Scale from: 0 to 4
Lower score = better
Biofeedback plus standard therapy: mean pain scores reduced from 2.2 to 0.0 after one
month and 0.6 after six months.
Sham biofeedback plus standard therapy: mean pain scores reduced from 2.1 to 0.6 af-










*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 





































































































































GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
a Downgraded one level for study limitations: inadequately reported methods lead us to consider this a high risk of bias study.
b Downgraded two levels for imprecision: a single small study with a confidence interval that includes both a small and very large eFect of intervention.
c Downgraded one level for imprecision: CI not estimable.
d Downgrading an additional level for study limitations: measures of variation and statistical significance were not reported.
 
 
Summary of findings 3.   Biofeedback compared to hypnotherapy for irritable bowel syndrome
Biofeedback compared to hypnotherapy for irritable bowel syndrome




Anticipated absolute effects* (95% CI)Outcomes




















Lower score = better
follow-up: 12 weeks
The mean score with hypnotherapy control
was 58.0 lower
MD 58.8 lower






Quality of life (QoL) Quality of life is included in the IBS-SSS outcome but is not reported separately in this
study.
- - -  
Adverse events (AE) Adverse events were not reported in this study. - - -  





































































































































Abdominal pain (Pain) Abdominal pain is included in the IBS-SSS outcome but is not reported separately in this
study.
- - -  
Depression
assessed with: depression
sub-score of the HADS
Lower score = better
The mean score with hypnotherapy control
was 5.9
MD 1.0 lower







assessed with: anxiety sub-
score of the HADS
Lower score = better
The mean score with hypnotherapy control
was 9.1
MD 0.7 higher






*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; MD: mean difference; RCT: randomized controlled trial; IBS-SSS: IBS severity scoring system; HADS: hospital anxiety and depression scale
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
a Downgraded one level for study limitations: overall high risk of bias.
b Downgraded one level for imprecision: a single small study with a confidence interval that includes both a very large and very small eFect.
c Downgraded one level for imprecision: a single small study with a confidence interval that spans no eFect.
 
 
Summary of findings 4.   Biofeedback compared to counseling for irritable bowel syndrome
Biofeedback compared to counseling for irritable bowel syndrome




Anticipated absolute effects* (95% CI)Outcomes


















































































































































Composite Primary Symptom Reduction
Score (CPSR)
Scale from: -100 to 100
Higher score = better
The mean score with counsel-
ing control was 31.46
MD 7.03 higher







assessed with: 50% improvement in










Quality of life (QoL)
assessed with: IBSIS
Both the biofeedback and cognitive therapy groups improved after treat-








assessed with: self report
  RD 0










Serious adverse events (SAE)   RD 0











Scale from: 0 to 4
Lower score = better
The mean score with counsel-
ing control was 0.65
MD 0.04 higher






*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; MD: mean difference; RCT: randomized controlled trial
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different





































































































































Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
a Downgraded one level for study limitations: unclear reporting and high dropout rates led us to consider this a high risk of bias study.
b Downgraded one level for imprecision: the confidence interval is wide and includes no eFect.
c Downgraded one level for possible publication bias: presumably AE would be measured in all trials, yet only one reported explicitly on them.
d Downgraded one level for imprecision: while the CI is narrow, the total number of participants is low (n = 29) and the CI includes no eFect.
e Downgraded one level for imprecision: while the CI is narrow, the total number of participants is low (n = 29).
f Downgraded two levels for study limitations (the study is at high risk of bias and the outcome is incompletely reported) and one level for serious imprecision (small sample size).
 
 
Summary of findings 5.   Multi-component psychological intervention (with biofeedback) compared to no-treatment control for irritable bowel
syndrome
Multi-component psychological intervention (with biofeedback) compared to no-treatment control for irritable bowel syndrome
Patient or population: people with irritable bowel syndrome
Setting: outpatient setting
Intervention: multi-component psychological intervention (with biofeedback)
Comparison: no-treatment control
Anticipated absolute effects* (95% CI)Outcomes


















Composite Primary Symptom Reduction
Score (CPSR)
Scale from: -100 to 100
higher score = better
follow-up: 8 weeks
The mean score with no treatment
ranged from 6.4 to 15.4
MD 30.34 higher








assessed with: 50% improvement in com-
posite symptom score
follow-up: 8 weeks











Quality of life (QoL) No formal quality of life scales were used in the included trials. - - -  
Adverse events (AE) Adverse events were not reported in these studies. - - -  







































































































































assessed with: symptom diaries
Lower score = better
follow-up: 8 weeks
The mean score with no treatment
ranged from 9.1 to 22.0
MD 1.4 lower








assessed with: Beck Depression Inventory
Lower score = better
The mean score with no treatment
ranged from 10.5 to 11.7
MD 3.8 lower








assessed with: State sub-score of the
state-trait inventory
Lower score = better
The mean score with no treatment
ranged from 42.2 to 44.5
MD 8.63 lower








assessed with: Trait sub-score of the
state-trait inventory
Lower score = better
The mean score with no treatment
ranged from 46.5 to 48.5
MD 3.98 lower







*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; MD mean difference; RCT: randomized controlled trial
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
a Downgraded one level for study limitations: lack of blinding and poor reporting on key risk of bias domains lead us to consider a high risk of bias for all trials.
b Downgraded one level for indirectness: this review was on whether biofeedback is safe and eFective for IBS, yet these meta-analyzed trials test a complex intervention which
includes biofeedback as well as other interventions.
c Downgraded one level for imprecision: the 95% confidence interval is wide and includes both a small and large eFect.








































































































































Summary of findings 6.   Multi-component psychological intervention (with biofeedback) compared to attention control for irritable bowel syndrome
Multi-component psychological intervention (with biofeedback) compared to attention control for irritable bowel syndrome
Patient or population: people with irritable bowel syndrome
Setting: outpatient setting
Intervention: multi-component psychological intervention (with biofeedback)
Comparison: attention control
Anticipated absolute effects* (95% CI)Outcomes


















Composite Primary Symptom Reduction
Score (CPSR)
Scale from: 0% to 100%
Higher score = better
follow-up: 8 weeks
The mean score with attention control
ranged from 30.2 to 38.0
MD 4.02 higher








assessed with: 50% improvement in











Quality of life (QoL) No formal quality of life scales were used in the included trials. - - -  
Adverse events (AE) Adverse events were not reported in these studies. - - -  
Serious adverse events (SAE) Serious adverse events were not reported in these studies. - - -  
Abdominal Pain (Pain)
assessed with: symptom diaries
Lower score=better
follow-up: 8 weeks
The mean score with attention control
ranged from 11.7 to 13.5
MD 0.72 higher








assessed with: Beck Depression Inven-
tory
Lower score = better
The mean score with attention control
ranged from 6.7 to 7.9
MD 0.13 higher













































































































































assessed with: State sub-score of the
state-trait inventory
Lower score = better
The mean score with attention control
ranged from 36.2 to 36.3
MD 0.74 lower








assessed with: Trait sub-score of the
state-trait inventory
Lower score = better
The mean score with attention control
ranged from 39.6 to 40.8
MD 2.05 higher







*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; MD: mean difference; RCT: randomized controlled trial
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
a Downgraded one level for imprecision: the 95% confidence interval includes both no eFect and eFect.
b Downgraded one level for study limitations: lack of blinding and poor reporting on key RoB domains lead us to consider a high risk of bias for both trials.
c Downgraded one level for indirectness: this review was on whether biofeedback is safe and eFective for IBS, yet these meta-analyzed trials test a complex intervention which
includes biofeedback as well as other interventions.
 
 
Summary of findings 7.   Biofeedback compared to relaxation training for irritable bowel syndrome
Biofeedback compared to relaxation training for irritable bowel syndrome




Anticipated absolute effects* (95% CI)Outcomes



























































































































































Lower score = better
The mean severity of symptoms in the biofeedback group was 3.20 at pretest and 2.80 post-






LOW a b c
 
Quality of life (QoL) No formal quality of life scales were used in the trial. - - -  
Adverse events (AE) Adverse events were not reported in this study. - - -  
Serious adverse events
(SAE)
Serious adverse events were not reported in this study. - - -  
Stool Frequency
assessed with: diary
Stool frequency was measured using patient diaries and a decrease in stool frequency was









assessed with: self report
There was no difference between groups in abdominal pain (only statistical tests, not sum-








assessed with: HCL 90-R
Scores from a depression subcategory of the HCL 90-R were reported. All groups had an im-
provement from baseline to post-treatment but that the between group comparisons were








assessed with: HCL 90-R
Scores from an anxiety subcategory of the HCL 90-R were reported. All groups had improve-
ment pre/post-treatment (P < 0.007) but the between group comparisons were equivalent







*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
RCT: randomized controlled trial
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect






































































































































a Downgraded one level for study limitations: high risk of bias study.
b Downgraded one level for imprecision: SD were not reported. The between group diFerence was small.
c Downgraded an additional level for study limitations: measures of variation and statistical significance were not reported.
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B A C K G R O U N D
Description of the condition
Irritable bowel syndrome (IBS) is a common disorder which aFects
an estimated 11% of individuals worldwide (Canavan 2014). Its
definition and diagnostic criteria have varied over the years, with
the most current version released by an international group of
experts in 2016 as Rome IV (Drossman 2016). In short, IBS is
a functional bowel disorder marked by chronic and recurrent
abdominal pain which improves with defecation, or worsens in
tandem with changes in stool frequency or consistency. IBS is
commonly divided into subtypes: diarrhea predominant (IBS-D),
constipation predominant (IBS-C), mixed (IBS-M), and unsubtyped
(IBS-U) (Drossman 2016).
Clinicians oMen have diFiculty achieving satisfactory control of
IBS symptoms. Pharmacologic treatments tend to be aimed at
symptom control, and eFective therapies that obtain or prolong
remission of symptoms are elusive (Halland 2015). These options
cross multiple categories of medication, and are oMen prescribed
based on the subtypes of the condition (Rao 2015). Multiple
psychological interventions have been given to people with IBS,
with varying degrees of success (Zijdenbos 2009).
We currently lack comprehensive data about the impact of IBS
on total healthcare expenditures. A review of over 3000 people
with IBS-C in the United States, compared to non-IBS controls,
concluded that the healthcare costs totaled 3856 US dollars (USD)
per patient per year (Doshi 2014). In China, direct annual patient
costs related to IBS are an estimated USD 763 per year (Fan 2017).
Description of the intervention
Biofeedback is "a process that enables an individual to learn how to
change physiological activity for the purposes of improving health
and performance" (AAPB 2016). Biofeedback sessions include real-
time monitoring of an individual's physiological signals, which are
then displayed back to the individual. Examples of such signals
include temperature fluctuations, skin conductance, heart rate
variability, muscle activity, and respiration patterns. In clinical
and educational settings, biofeedback is mostly conducted using
computerized models that use graphs, images and sounds to give
feedback on these signals to the person. The goal of biofeedback is
to use this feedback to help an individual develop self-awareness
of their physiological states. In theory, this awareness may lead
to better control over autonomic activity, and improved health
outcomes (Peper 2009).
One illustrative example of biofeedback in a clinical setting would
be the use of a clip-on ear lobe probe that measures heart rate
variability during a relaxing meditation session. The goal of this
type of exercise would be to help a person recognize and reproduce
a relaxed state during times of stress (Wheat 2010).
How the intervention might work
The etiology of IBS is still not fully elucidated, and may
incorporate multiple domains, including colonic dysmotility,
visceral hypersensitivity, immunologic, microbiotic, and dietary
factors, as well as elements of brain-gut interaction (Lee 2014).
In regards to the latter, researchers have identified a disturbance
in sympatho-vagal balance in IBS suFerers when compared to
controls (Pellissier 2010; Sowder 2010).
The autonomic nervous system is comprised of three branches,
including the sympathetic, parasympathetic and enteric nervous
systems. Through these three divisions, the autonomic nervous
system influences gastrointestinal motility, secretion and immune
function (Elenkov 2000; Hansen 2003). Increased sympathetic and
reduced parasympathetic nervous system activity is the most
common pattern observed in people with IBS, when compared to
controls (Manabe 2009).
Modulation of the autonomic nervous system, to favor increased
sympathetic and reduced parasympathetic activity, is a key
component of the stress response. Subsequent changes in
gastrointestinal function that result from this pattern of
stress modulation are one potential mechanism underlying IBS
symptoms (Manabe 2009).
Biofeedback has been proposed to help users gain some control
over physiologic processes, including sympatho-vagal balance (e.g.
autonomic nervous system function). Research in other functional
bowel disorders (e.g. functional abdominal pain) has demonstrated
that biofeedback can improve sympatho-vagal balance and disease
symptomatology (Sowder 2010). Biofeedback interventions have
been studied in other gastrointestinal conditions. For instance,
biofeedback has been used to manage functional constipation
(Woodward 2014), and fecal incontinence (Norton 2012). Many
functional bowel disorders have overlapping symptomatology,
and in some instances are beginning to be viewed as diFerent
ends of a continuum of symptom presentations (Drossman 2016).
Considering the positive, though preliminary, evidence for the
benefit of biofeedback in other gastrointestinal conditions with
symptoms which overlap that of IBS, we wished to investigate the
eFicacy of biofeedback interventions in IBS.
Why it is important to do this review
Irritable bowel syndrome is a common functional bowel disorder
that is associated with impaired quality of life and increased
healthcare costs, but which lacks reliable treatment options (Lee
2014). Biofeedback-based interventions are a group of low risk
interventions that have been shown to be potentially eFective in
IBS (Dobbin 2014). To our knowledge, the available randomized
trial evidence on using biofeedback for IBS has not previously been
systematically reviewed.
O B J E C T I V E S
Our primary objective was to assess the eFicacy and safety of
biofeedback-based interventions for IBS in adults and children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) of biofeedback
treatment for IBS. We included studies that used active treatment,
no treatment, sham treatment, or placebo as a control. We did not
apply any language restrictions, and included studies published
either as abstracts or full papers.
Types of participants
Our inclusion criteria specified that participants should be adults
or children diagnosed with IBS, as defined by the trial authors. As
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the diagnostic criteria for IBS have changed over time (Drossman
2016), we chose to be as inclusive as possible to minimize selection
bias. However, diFering diagnostic criteria was one of our a
priori subgroups to explore potential heterogeneity (see Subgroup
analysis and investigation of heterogeneity).
Types of interventions
We included trials investigating all forms of biofeedback.
If the trial authors had not explicitly described an
intervention as biofeedback, we used the Association for
Applied Psychophysiology and Biofeedback’s (AAPB) definition of
biofeedback to guide eligibility decisions (AAPB 2016).
This definition describes biofeedback as, “a process that enables
an individual to learn how to change physiological activity for
the purposes of improving health and performance. Precise
instruments measure physiological activity such as brainwaves,
heart function, breathing, muscle activity, and skin temperature.
These instruments rapidly and accurately 'feed back' information
to the user. The presentation of this information — oMen in
conjunction with changes in thinking, emotions, and behavior —
supports desired physiological changes. Over time, these changes
can endure without continued use of an instrument" (AAPB 2016).
We also included studies that used other treatment modalities in
addition to biofeedback (e.g. progressive muscle relaxation). We
did not, however, pool these studies with biofeedback-only trials.
Some of these studies used relaxation training techniques without
biofeedback as the control group in their research methodology.
We used the term 'attention control' to represent 'relaxation
training without biofeedback' throughout the review.
Types of outcome measures
Primary outcomes
• Global or clinical improvement, as defined by the included
studies (e.g. IBS Severity Scoring System [IBS-SSS], or the
Gastrointestinal Symptom Rating Scale [GSRS])
• Quality of life (e.g. overall well-being, Irritable Bowel Syndrome
Quality of Life questionnaire [IBS-QoL], Short Form Health
Survey [SF-36])
Secondary outcomes
• Adverse events (if available, using the National Institute for
Health (NIH) Common Terminology Criteria for Adverse Events
version 4.0)
• Withdrawal due to adverse events
• Serious adverse events
• Stool frequency
• Stool consistency (e.g. as rated by the Bristol Stool Scale)
• IBS-C stool frequency weekly responder (defined as a
participant who experiences an increase of at least one complete
spontaneous bowel movement per week from baseline; FDA
2012; MacDougall 2013.)
• IBS-D stool frequency weekly responder (defined as a 50% or
more reduction in the number of days per week with at least one
stool that has a Bristol consistency score of type 6 or 7, compared
with baseline; FDA 2012.)
• Improvement in abdominal pain frequency and severity
• Depression (e.g. Beck Depression Inventory)
• Anxiety (e.g. State-Trait Anxiety Inventory)
Search methods for identification of studies
Electronic searches
We searched the following databases from inception to 24 July
2019:
• the Cochrane Inflammatory Bowel Disease (IBD) Group
Specialized Register;
• the Cochrane Central Register of Controlled Trials (CENTRAL);
• MEDLINE;
• Embase;
• the Cumulative Index to Nursing and Allied Health Literature
(CINAHL); and
• the Allied and Complementary Medicine Database (AMED).
We customized the search strategies for each database and used
the recommended Cochrane search string for the identification
of RCTs. We did not apply any language restrictions. Appendix 1
reports the search strategies.
Searching other resources
We searched for additional, ongoing and unpublished studies
through the following additional resources, including the grey
literature:
• reference lists of included studies, and those of any relevant
systematic reviews identified;
• clinical trial registries: ClinicalTrials.gov (clinicaltrials.gov),
ICTRP (www.who.int/ictrp/en/) and ISRCTN Registry
(www.isrctn.com/);
• contacting biofeedback device manufacturers, researchers
and practitioners to determine knowledge of ongoing or
unpublished trials;
• searching for published abstracts from conference proceedings:
Biosis Citation Index, Scopus, Web of Science;
• reviewing theses and dissertations in ProQuest Dissertations &
Theses Global; and
• searching open Access Journals: Directory of Open Access
Journals and Highwire Press.
Data collection and analysis
Selection of studies
A research librarian (JB) conducted the search and compiled
identified papers into a citation manager. Four of the authors (JG,
MB, MH, RB) worked in pairs, independently and in duplicate,
to review these citations for inclusion, based on the criteria
described in Criteria for considering studies for this review. First,
they screened at the title level, then they reviewed the included
papers at the abstract level. Finally, they reviewed the full text
of the remaining papers against the inclusion criteria, using a
standardized inclusion form. Throughout the process, the review
authors resolved disagreements by consensus. At all stages, the
review authors noted the reasons for exclusion. We asked a
translator to assess any non-English language papers. To limit
selection bias, we also included studies that were published as
abstract only. We attempted to contact the abstracts' authors for
further details, including final results.
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Data extraction and management
Two authors (JG, MB) extracted data from the Included papers
independently and in duplicate, and resolved any disagreements
by consensus. They used a standardized extraction form to collect
the following information:
• author;
• year of publication;
• language;
• study setting (country, inpatient, outpatient);
• funding source;
• inclusion and exclusion criteria for participants;
• participant characteristics (age, gender, diagnosis,
socioeconomic status);
• number of participants randomized to each group;
• presence or absence of intention-to-treat analysis (whether
participants for whom data were available were analyzed as
randomized);
• participants lost to follow-up (LTFU), with reasons for LTFU
described, and information about any methods of imputation
used within the primary analysis;
• measures of compliance;
• type of biofeedback used;
• duration and frequency of biofeedback;
• duration of study period;
• duration of follow-up;
• co-interventions;
• disease severity at baseline;
• primary and secondary outcomes, as defined by study authors;
• outcome instruments used;
• symptoms (e.g. pain, bloating);
• quality of life (e.g. overall well-being, IBS-QoL);
• adverse events (using NIH Common Terminology Criteria for
Adverse Events version 4.0 ideally, but per author definition if
common terminology criteria were not available);
• stool frequency;
• stool consistency (e.g. Bristol Stool Scale);
• IBS-C stool frequency weekly responder (defined as a
participant who experiences an increase of at least one complete
spontaneous bowel movement per week from baseline);
• IBS-D predominant stool frequency weekly responder (defined
as a 50% or more reduction in the number of days per week with
at least one stool that has a consistency of type 6 or 7 compared
with baseline);
• improvement in abdominal pain frequency and severity;
• depression; and
• anxiety.
We attempted to contact all trial researchers to clarify missing data,
or to ask for relevant unpublished data. We made attempts to
contact first, corresponding, and senior authors.
Assessment of risk of bias in included studies
We evaluated each of the included studies with the Cochrane
'Risk of bias' tool, to assess sequence generation, allocation
concealment, blinding of participants and personnel, blinding
of outcome assessment, incomplete outcome data, selective
outcome reporting, and other sources of bias (Hartling 2009;
Higgins 2011). Two authors (JG, MB) reviewed the studies
independently and in duplicate, and resolved any disagreement by
consensus. If we were unable to clarify missing risk of bias domains,
we assessed studies as having an unclear risk of bias.
We know from well-conducted placebo studies on IBS that
elaborate placebo comparisons can yield very high non-specific
(placebo) eFects (Kaptchuk 2008). We also know from this work that
the magnitude of non-specific eFects can be substantial and vary
depending upon the level of elaborateness, physician interaction,
ritual etc. Because IBS can have such a large placebo response and
the magnitude of that response depends substantially on the level
of elaborateness of the control (the extent of which is not always
clear in published work), we adopted the following decision making
process in evaluating our trials for risk of performance bias.
• Biofeedback versus no-treatment control was assessed as high
risk of bias
• Biofeedback versus active control was assessed as unclear risk
of bias
• Biofeedback versus attention control was assessed as unclear
risk of bias
We also employed the GRADE system for rating overall certainty
of evidence. In particular, randomized trials begin as high quality
evidence, but may be rated down by one or more of five categories
of limitations: (1) risk of bias, (2) consistency, (3) directness, (4)
imprecision, and (5) reporting bias. The certainty of evidence for
each main outcome can be determined aMer considering each
of these elements, and categorized as either high (we are very
confident that the true eFect lies close to that of the estimate of
the eFect); moderate (we are moderately confident in the eFect
estimate: the true eFect is likely to be close to the estimate of the
eFect, but there is a possibility that it is substantially diFerent); low
(our confidence in the eFect estimate is limited: the true eFect may
be substantially diFerent from the estimate of the eFect); very low
(we have very little confidence in the eFect estimate: the true eFect
is likely to be substantially diFerent from the estimate of eFect)
(Guyatt 2008).
Measures of treatment e:ect
We presented dichotomous data as risk ratios (RR), and continuous
data as mean diFerences (MD), with corresponding 95% confidence
intervals (CI). Using control event risks from the included trials, we
calculated the number needed to treat for an additional beneficial
outcome (NNTB) or the number needed to treat for an additional
harmful outcome (NNTH).
Unit of analysis issues
To avoid unit of analysis issues, we chose the first intervention
phase of any identified cross-over study for our analysis. Likewise,
for multiple intervention arm trials, we planned to split the control
group in order to avoid unit of analysis issues. Finally, for studies
with repeated observations on trial participants, we only used one
data point from the participant. For example, if a trial reported
multiple adverse events per participant, we used the total number
of participants with adverse events for our analysis, rather than the
total number of adverse events.
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Dealing with missing data
We noted information about missing outcome data at the data
extraction stage. We considered trials that had 10% or more
missing outcome data to have a high risk of bias for the attrition
domain of the Cochrane 'Risk of bias' tool. In line with recent
recommendations, we used a complete case analysis for our
primary analysis, but when relevant, we carried out a sensitivity
analysis to assess the potential influence of missing outcome data
on our primary outcomes (Guyatt 2017; Akl 2015; Ebrahim 2013).
For these sensitivity analyses, we elected to make assumptions
about the missing data that were extreme but also plausible. For
example, for the dichotomous outcome of adverse events, we
would assume that the missing participants in the control group
had adverse events at the same rate as those analyzed, while
for the biofeedback group we would assume that their missing
participants had adverse events at rates of 1.5:1, 2:1, 3:1, and 5:1
of those analyzed. We would then ascertain if the eFect estimate
survived the extreme plausible assumptions (Guyatt 2017; Akl 2015;
Ebrahim 2013).
When trials did not report standard deviations (SD) and we were
unable to contact the authors, we estimated the SD from the t value,
if available, as per the Cochrane Handbook (Section 7.7.3).
Assessment of heterogeneity
Heterogeneity in systematic reviews is generally described as
clinical, methodological, and statistical (Deeks 2011). The former
two may or may not be reflected within formal tests for
statistical heterogeneity, but may still be present and important
to investigate (Gagnier 2013). We therefore followed the proposed
13 recommendations for assessing and investigating clinical
heterogeneity in systematic reviews (Gagnier 2013). Appendix 2
describes this approach.
Statistical heterogeneity was investigated using the I2 statistic using
the following thresholds as a guide, as per the Cochrane Handbook
for Systematic Reviews of Interventions: 0% to 40% might not be
important; 30% to 60% may represent moderate heterogeneity;
50% to 90% may represent substantial heterogeneity; and 75% to
100% may indicate considerable heterogeneity (Deeks 2011).
Assessment of reporting biases
We attempted to identify protocols of included trials via trial
registries (e.g. ClinicalTrials.gov). If found, we planned to compare
protocols with published papers to look for reporting biases. To
evaluate the potential for publication bias and other small study
eFects, we were to follow published guidelines and inspect the
funnel plots of each outcome for visual evidence of asymmetry
and, when appropriate, conduct Harbord’s linear regression test
to investigate statistical evidence of small study eFects (Harbord
2006; Sterne 2011). As per the guidelines, we did not conduct a
funnel plot, as there were fewer than 10 trials included in the meta-
analysis (Sterne 2011).
Data synthesis
We combined data in a meta-analysis using a fixed-eFect model for
the primary analysis, and conducted a sensitivity analysis using a
random-eFects model. We used a fixed-eFect model because the
only trials that could be combined used identical interventions. We
also considered a fixed-eFect model to be appropriate given the
limitations of estimating between-study heterogeneity with so few
studies.
Subgroup analysis and investigation of heterogeneity
Investigation of heterogeneity, including using subgroup
analyses, is described in Appendix 2. In short, the consensus
recommendations for heterogeneity investigation as per the 2013
heterogeneity Delphi group findings were followed (Gagnier 2013).
In addition, we planned to subject all subgroup analyses to a
credibility checklist, as proposed by Sun and colleagues (Sun 2012).
Sensitivity analysis
We conducted both fixed-eFect and random-eFects meta-analyses.
Additionally, we followed the GRADE guidance on handling missing
participant outcome data (Guyatt 2017). That is, when pooled
estimates were statistically significant, we imputed outcome data
that were missing, to challenge the robustness of the pooled
estimates (Guyatt 2017). For dichotomous outcomes, we assumed
that the missing participants in the control group had a clinical
response at the same rate as those successfully followed, while for
the biofeedback group we assumed their missing participants had
a clinical response at progressively worse rates when compared to
those successfully followed. For continuous outcomes, we imputed
means for missing outcome data assuming increasingly strict
assumptions and, as recommended, used the median SD of the
control group of the included trials for variability of the imputed
data. Unlike the best-case, worst-case scenario, the assumptions
are plausible but not extreme.
R E S U L T S
Description of studies
Results of the search
The primary literature search identified 1497 records, with the
grey literature search identifying an additional 3542 records. AMer
removal of duplicates, we screened 4353 records and selected 167
full text articles for further review. Of these, eight trials (in seven
publications) met our inclusion criteria and we included these
in our qualitative synthesis. The studies by Blanchard 1992a and
Blanchard 1992b were two separate studies reported within a single
publication. Four outcomes (clinical response, abdominal pain,
depression, and anxiety) had trials with suFiciently homogenous
treatment and outcome measures to allow for meta-analysis for
two comparisons (active versus no-treatment control and active
versus attention control).
We included three studies in the qualitative synthesis for the
comparison 'active versus no-treatment control' (Blanchard 1992a;
Blanchard 1992b; NeF 1987), and two studies for the quantitative
synthesis of 'active versus attention control' (Blanchard 1992a;
Blanchard 1992b). See Figure 1 for the PRISMA study flow diagram.
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Figure 1.   PRISMA study flow diagram.
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Figure 1.   (Continued)
 
Included studies
We have summarized the key characteristics of the included studies
below, with further details in the Characteristics of included studies
table.
Design
All included trials were randomized controlled trials as per our
inclusion criteria. Four trials used three arms (Blanchard 1992a;
Blanchard 1992b; DeRoo 1988; Trembach 2009), the remaining
trials were two armed trials.
The Characteristics of included studies table gives further details
about study design.
Sample sizes
The included studies ranged in size from 13 to 92 participants. There
was a total of 300 subjects across the eight included trials.
Setting
All trials were in an outpatient setting and enrolled community-
dwelling individuals.
Participants
All trials enrolled adults only. All of the trials exclusively enrolled
participants with irritable bowel syndrome. One study enrolled
people with IBS-D only (DeRoo 1988), one study enrolled people
with IBC-C only (Trembach 2009), no studies exclusively enrolled
people with IBS-M, and the remaining six studies were not
exclusive to a single IBS subtype. Two studies exclusively enrolled
women (Dobbin 2013; Trembach 2009). The diagnostic criteria
used to determine IBS diagnosis were heterogeneous, but each
trial required that a medical professional should have made the
diagnosis.
Interventions
The type and duration of biofeedback intervention varied from trial
to trial. Interventions included multi-component interventions,
such as including progressive muscle relaxation (e.g. Blanchard
1992a), as well as exclusively biofeedback intervention arms (e.g.
Thompson 2010). The Characteristics of included studies table
gives further details of the types of biofeedback interventions.
Comparators
Comparators varied among trials and included active controls (e.g.
Dobbin 2013), attention controls (e.g. Blanchard 1992a), wait-list
controls (e.g. Blanchard 1992b), and sham biofeedback controls
(e.g. DeRoo 1988). The Characteristics of included studies table
summarizes the details about comparators.
Outcomes
Outcome measures exhibited significant heterogeneity and
included the IBS-SSS (Dobbin 2013) and the IBS impact scale
(Thompson 2010) among many others. Of the outcomes used, only
the composite primary symptom reduction score (CPSR) was used
by multiple studies, Four trials used the CPSR (Blanchard 1992a;
Blanchard 1992b, NeF 1987; Thompson 2010). The Characteristics
of included studies table gives further details of each trial's
outcome assessment.
Funding Sources
None of the included studies reported funding sources clearly.
Excluded studies
We excluded 4177 records at the title and abstract stage of study
selection. We were unable to acquire the full text of nine studies
that we had selected for further review, despite considerable eFort
by the review authors and supplementary librarian support. Of the
167 full text studies reviewed, we excluded 160 for the following
reasons: 55 not IBS, 53 not RCT, 48 not biofeedback, 1 inadequate
control group, 2 were duplicate reports of already included
studies, and 1 a poster of a previously identified publication. The
‘Characteristics of excluded studies’ table gives some examples of
excluded studies.
Risk of bias in included studies
We considered the overall risk of bias to be high or unclear in all
included trials, primarily with respect to blinding (Figure 2; Figure
3). We describe below the risk of bias by domain, and give further
details in the Characteristics of included studies table.
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
Allocation
Only two included trials described the randomization process, and
we judged these to have a low risk of bias (Dobbin 2013; Thompson
2010). The others did not describe this process, and we judged
these to have an unclear risk of bias. Similarly, none of the included
papers described allocation concealment, so we judged them all to
have an unclear risk of bias.
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Blinding
Four of the included trials were clearly unblinded, so we judged
these to have a high risk of bias in both blinding domains
(performance bias and detection bias) (DeRoo 1988; Leahy 1997;
NeF 1987; Trembach 2009). In the other four trials, it was unclear
whether participants and personal were blind to which of the active
groups was the group of interest, so we judged these to have an
unclear risk of bias (Blanchard 1992a; Blanchard 1992b; Dobbin
2013; Thompson 2010).
Incomplete outcome data
Using our a priori cut-oF of 10% dropouts as a rationale for a high
risk of attrition bias, we judged one of our included studies to have
a high risk of bias in this domain (Blanchard 1992b). One trial did
not include information on dropouts, so we judged this to have an
unclear risk of bias (Leahy 1997). The other six trials had fewer than
10% dropouts, so we judged them to be at low risk of attrition bias
(Blanchard 1992a; DeRoo 1988; Dobbin 2013; NeF 1987; Thompson
2010; Trembach 2009).
Selective reporting
One of our included trials (NeF 1987) used a composite score that
was diFerent from the outcome measure used in a pilot trial by the
same research team. We judged this to be suspicious for selective
outcome reporting bias. Two of the other trials did not include
suFicient information about how the scales were developed or
whether any further data were collected, so we rated these as an
unclear risk of bias (Leahy 1997; Trembach 2009). We judged the
other five trials to have a low risk of bias in this domain (Blanchard
1992a; Blanchard 1992b; DeRoo 1988; Dobbin 2013; Thompson
2010).
Other potential sources of bias
One trial was reported as an abstract only, and we were
unsuccessful in making follow-up contact with the authors (Leahy
1997). We therefore judged this to have an unclear risk of bias in this
domain. We did not consider that the other trials had important risk
of bias issues with respect to baseline distribution, stopping early
for benefit, or any other undefined reason. We therefore judged
these to be at low risk of other bias.
E:ects of interventions
See: Summary of findings for the main comparison Biofeedback
plus standard therapy compared to standard therapy for irritable
bowel syndrome; Summary of findings 2 Biofeedback plus
standard therapy compared to sham biofeedback plus standard
therapy for irritable bowel syndrome; Summary of findings
3 Biofeedback compared to hypnotherapy for irritable bowel
syndrome; Summary of findings 4 Biofeedback compared
to counseling for irritable bowel syndrome; Summary of
findings 5 Multi-component psychological intervention (with
biofeedback) compared to no-treatment control for irritable bowel
syndrome; Summary of findings 6 Multi-component psychological
intervention (with biofeedback) compared to attention control for
irritable bowel syndrome; Summary of findings 7 Biofeedback
compared to relaxation training for irritable bowel syndrome
The included trials evaluated the eFects of biofeedback for IBS
across seven comparisons. The summary of findings tables for
clinical improvement, quality of life, adverse events, serious
adverse events, abdominal pain, depression, and anxiety for each
comparison can be found: Summary of findings for the main
comparison (Biofeedback plus standard therapy versus standard
therapy), Summary of findings 2 (Biofeedback plus standard
therapy versus sham biofeedback versus standard therapy),
Summary of findings 3 (Biofeedback versus hypnotherapy),
Summary of findings 4 (Biofeedback versus counseling), Summary
of findings 5 (Multi-component psychological intervention (with
biofeedback) versus no-treatment control), Summary of findings
6 (Multi-component psychological intervention (with biofeedback)
versus attention control), Summary of findings 7 (Biofeedback
versus relaxation training). We have reviewed the results of these
comparisons by outcome below.
Primary outcomes
Global or clinical improvement
The included studies used numerous measures of global or
clinical improvement. They are delineated below, organized by
comparison.
Biofeedback plus standard therapy versus standard therapy
Trembach 2009 reported on clinical improvement by stratifying the
participants' six month results by no improvement, inadequate
improvement, significant improvement, and remission. One
hundred per cent (10/10) of participants reached adequate
improvement or remission with standard therapy (fiber and
medication) plus biofeedback at six months compared to 20%
(2/10) of the participants receiving standard therapy alone (RR 4.20,
95% CI 1.40 to 12.58; n = 20; P = 0.01; NNTB = 1, very low-certainty
evidence) (Figure 4; Analysis 1.1)
 
Figure 4.   Forest plot of comparison: 1 Biofeedback plus Standard Therapy versus Standard Therapy, outcome: 1.1
Clinical Response.
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Biofeedback plus standard therapy versus sham biofeedback plus
standard therapy
Trembach 2009 reported on clinical improvement by stratifying the
participants' six month results by no improvement, inadequate
improvement, significant improvement, and remission. One
hundred per cent (10/10) of participants reached adequate
improvement or remission with standard therapy (fiber and
medication) plus biofeedback at six months compared to 40%
(4/10) of participants receiving standard therapy plus sham
biofeedback (RR 2.33, 95% CI 1.13 to 4.80, n = 20; P = 0.02; NNTB =
2; very low-certainty evidence) (Figure 5; Analysis 2.1).
 
Figure 5.   Forest plot of comparison: 2 Biofeedback plus Standard Therapy versus Sham Biofeedback plus Standard
Therapy, outcome: 2.1 Clinical Response.
 
Biofeedback versus hypnotherapy
Using the 500 point IBS-SSS, Dobbin 2013 reported a 58.8 point
diFerence in favor of heart rate variability biofeedback, between
the biofeedback group and the hypnotherapy active control at 12
weeks (MD -58.80, 95% CI -109.11 to -8.49; n = 61; P = 0.02; low-
certainty evidence) (Figure 6; Analysis 3.1).
 




Thompson 2010 used heart rate variability biofeedback as a single
intervention compared to a cognitive therapy active control in their
eight-week, two-armed trial (29 participants). They also used the
CPSR as a measure of clinical improvement. They reported a greater
improvement in the biofeedback group (mean = 38.5) compared to
the cognitive therapy group (mean = 31.5), but the diFerence was
small and the eFect of chance cannot be ruled out (MD 7.03, 95%
CI -51.07 to 65.13; n = 29, P = 0.81, low-certainty evidence) (Figure
7; Analysis 4.1). When evaluated for clinical response using a 50%
improvement in CPSR score as a cut-oF, a similar percentage of
participants achieved clinical response at eight weeks. Specifically,
46.7% (7/15) of the biofeedback group achieved clinical response
compared to 45.5% (6/14) of participants in the cognitive therapy
group (RR 1.09, 95% CI 0.48 to 2.45; n = 29; P = 0 .84, low-certainty
evidence) (Figure 8; Analysis 4.2). The eFect was small and chance
cannot be ruled out.
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Figure 8.   Forest plot of comparison: 4 Biofeedback versus Counseling, outcome: 4.2 Clinical Response (complete
case).
 
Thompson 2010 also used the Cognitive Scale for Functional Bowel
Disorders (CSFBD) as a measure of clinical improvement. This is
a 25-item questionnaire that assesses the cognitions associated
with functional bowel disorders on a scale of 1 to 7, generating
a score between 25 and 175. Participants in the biofeedback and
cognitive behavioral therapy group both improved on the CSFBD
from baseline, but the trial authors did not note any between group
diFerences, presented only statistical tests and did not provide
summary eFect sizes.
In a conference abstract report of a small RCT of 21 participants.
Leahy 1997 compared electrocutaneous monitoring biofeedback
to counseling, and measured "symptom scores" without further
explanation. They reported that “counseling had no eFect on
symptom score”, with a change in median symptom score from 8.4
to 8.3 over the length of the study (Leahy 1997). The biofeedback
arm was not reported as a complete arm, but rather as 'responders',
with a median symptom score change of 7.7 to 5.6 over the length of
the study, and 'non-responders', with a median score change from
7.8 to 8.5. Leahy 1997 did not adequately report the total endpoint
scores between groups or statistical tests, making any eFect of
biofeedback diFicult to interpret. The trial authors did not describe
the type of counseling.
Multi-component psychological intervention (with biofeedback)
versus no-treatment control
The CPSR score was a commonly used composite outcome
measure for clinical improvement. With this measure, the larger
the score, the larger the percentage reduction in IBS symptoms,
with scores ranging from -100 to 100. Four trials used this measure,
three of which examined the comparison of multi-component
psychological intervention (with biofeedback) versus no-treatment
control (Blanchard 1992a; Blanchard 1992b; NeF 1987). In the
pooled analysis of these three trials, the mean diFerence
favored the multi-component psychological intervention (with
biofeedback) group compared to no-treatment control (MD 30.34,
95% CI 8.47 to 52.21; n = 101; P = 0.007; I2 = 0%; very low-certainty
evidence) (Figure 9; Analysis 5.1). These three studies also used an
a priori determined 50% improvement in the CPSR score as a cut-
oF for 'clinical response'. In a pooled analysis, 55% (28/51) of the
biofeedback group achieved clinical response compared to 26%
(13/50) of the no-treatment control group (RR 2.12, 95% CI 1.24
to 3.62; NNTB = 4; n = 101, P = 0.006, I2 = 0%, very low-certainty
evidence) (Figure 10; Analysis 5.7).
 
Figure 9.   Forest plot of comparison: 5 Multicomponent Psychological Intervention (with Biofeedback) versus no-
treatment control, outcome: 5.1 Symptom Improvement (measured by CPSR).
 
 
Figure 10.   Forest plot of comparison: 5 Multicomponent Psychological Intervention (with Biofeedback) versus no-
treatment control, outcome: 5.7 Clinical Response (complete case).
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Multi-component psychological intervention (with biofeedback)
versus attention control
Two studies compared a multi-component psychological
intervention (with biofeedback) to an attention control (Blanchard
1992a; Blanchard 1992b). These studies used the CPSR score to
measure clinical improvement. In the pooled analysis of these
two studies, there was a marginal mean diFerence favoring the
biofeedback group, but the eFect of chance could not be ruled out
(MD 4.02, 95% CI -21.41 to 29.45; n = 80; P = 0.76; I2 = 0%; very
low-certainty evidence) (Figure 11; Analysis 6.1). When evaluated
for clinical response using a 50% improvement in CPSR score as an
a priori cut-oF, in pooled analysis (Figure 12; Analysis 6.2), a similar
percentage of participants achieved clinical response at eight
weeks. Specifically 54% (22/41) of the biofeedback group achieved
clinical response compared to 49% (19/39) in the attention control
group and the eFect of chance could not be ruled out (RR 1.10, 95%
CI 0.72 to 1.69; n = 80, P = 0.67, I2 = 0%, very low-certainty evidence).
 
Figure 11.   Forest plot of comparison: 6 Multicomponent Psychological Intervention (with Biofeedback) versus
attention control, outcome: 6.1 Symptom Improvement (measured by CPSR).
 
 
Figure 12.   Forest plot of comparison: 6 Multicomponent Psychological Intervention (with Biofeedback) versus
Attention control, outcome: 6.2 Clinical Response (complete case).
 
Biofeedback versus relaxation training
DeRoo 1988 compared rectosigmoidal biofeedback (n = 5) with
a relaxation control (n = 5) and measured clinical improvement
by severity of symptoms over eight weeks. The mean severity of
symptoms in the biofeedback group was 3.20 at pretest and 2.80
post-test. The relaxation control group mean severity was 3.50
pretest and 2.50 post-test. The trial authors did not report standard
deviations or between-group statistical tests.
Quality of life outcomes
Thompson 2010 used the Irritable Bowel Syndrome Impact Scale
(IBS-IS), a 7-point quality of life scale that assesses impact of IBS
on fatigue, daily activities, sleep, emotional health, and eating
habits. None of the included trials used any other formal quality
of life scales. Thompson 2010 compared heart rate variability
biofeedback to a cognitive therapy active control in an eight week,
two-armed trial (n = 29). The trial authors reported that both the
biofeedback and cognitive therapy groups showed improvement in
their IBS-IS score, but did not note any between-group diFerences
or report any outcome data.
Secondary outcomes
Adverse events
While no adverse events were reported by any of the eight studies,
only Thompson 2010 explicitly reported on adverse events (RD 0.00,
95% CI -0.12 to 0.12, n = 29, P = 1.00, low-certainty evidence) (Figure
13, Analysis 4.3; Figure 14; Analysis 4.4).
 
Figure 13.   Forest plot of comparison: 4 Biofeedback versus Counseling, outcome: 4.3 Adverse Events.
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Figure 14.   Forest plot of comparison: 4 Biofeedback versus Counseling, outcome: 4.4 Serious Adverse Events.
 
Withdrawal due to adverse events
None of the studies reported any withdrawals due to adverse
events.
Serious adverse events
None of the studies reported any serious adverse events.
Stool frequency
None of the trials reported outcome-level data for stool frequency.
However, DeRoo 1988 measured stool frequency using participant
diaries, and reported a decrease in stool frequency in all three study
arms (but did not report outcome-level data for between-group
diFerences).
Stool consistency
Trembach 2009 used the Bristol Stool Scale (BSS) to report stool
consistency. Mean BSS scores improved from 1.4 to 4 in the
biofeedback group, and from 1.0 to 1.6 in the active controls.
The trial authors did not report statistical tests of between-group
diFerences.
IBS-constipation predominant stool frequency weekly responder
(FDA definition)
None of the studies used this outcome.
IBS-diarrhea predominant stool frequency weekly responder
(FDA definition)
None of the studies used this outcome.
Improvement in abdominal pain
Nine of the studies reported outcome-level data on abdominal
pain (Blanchard 1992a; Blanchard 1992b, DeRoo 1988; NeF 1987;
Thompson 2010, Trembach 2009). These studies reported on
results from six comparisons as delineated below, grouped by
comparison.
Biofeedback plus standard therapy versus standard therapy
Trembach 2009 had participants rate their abdominal pain using a
scale of 0 to 3 (no pain to severe). Mean pain scores reduced from 2.2
to 0.0 aMer one month and 0.6 aMer six months in the biofeedback
plus standard therapy group, compared with a drop from 2.2 to 0.6
aMer one month and 1.2 aMer six months in the standard therapy
group. The trial authors did not provide SD or P values.
Biofeedback plus standard therapy versus sham biofeedback plus
standard therapy
Trembach 2009 had participants rate their abdominal pain using a
scale of 0 to 3 (no pain to severe). Mean pain scores reduced from 2.2
to 0.0 aMer one month and 0.6 aMer six months in the biofeedback
plus standard therapy group compared with a drop from 2.1 to 0.6
aMer one month and 1.0 aMer six months in the standard therapy
group. The trial authors did not provide SD or P values.
Biofeedback versus counseling
Thompson 2010 used a 0 to 4-point scale (no pain to severe pain) to
track abdominal pain levels, and reported similar decreases in pain
levels in both groups. The trial authors reported mean pain ratings
post-treatment of 0.650 and 0.695 respectively for cognitive therapy
and biofeedback (MD 0.04, 95% CI -0.43 to 0.52; n = 29; P = 0.85;
low certainty evidence) (Figure 15; Analysis 4.5). The diFerence was
small and chance cannot be ruled out.
 
Figure 15.   Forest plot of comparison: 4 Biofeedback versus Counseling, outcome: 4.5 Abdominal Pain.
 
Multi-component psychological intervention (with biofeedback)
versus no-treatment control
The three trials that compared multi-component psychological
intervention including biofeedback versus no-treatment control all
used symptom diaries to track abdominal pain, on a scale that
was not fully described (Blanchard 1992a; Blanchard 1992b; NeF
1987). NeF 1987 did not provide enough information for pooling,
but reported that mean abdominal pain scores improved during
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the length of the study in both the biofeedback and no-treatment
control group (6.82 to 2.54 and 9.36 to 8.80 respectively). The
authors only reported that the eFects of biofeedback were not
statistically significant (they did not provide the P values and
it is unclear if they are referring to a between-group or within-
group comparison). Using pooled data from Blanchard 1992a and
Blanchard 1992b, the pooled mean diFerence post-treatment using
this abdominal pain scale favored the biofeedback arm (MD -1.40,
95% CI -7.54 to 4.74; n = 82; P = 0.66; very low-certainty evidence)
(Figure 16; Analysis 5.11) but the eFect was small and chance
cannot be ruled out.
 
Figure 16.   Forest plot of comparison: 5 Multicomponent Psychological Intervention (with Biofeedback) versus No-
treatment control, outcome: 5.11 Abdominal Pain.
 
Multi-component psychological intervention (with biofeedback)
versus attention control
The two trials that compared multi-component psychological
intervention including biofeedback versus attention control used
symptom diaries to track abdominal pain using a scale that
was not fully described (Blanchard 1992a; Blanchard 1992b). The
pooled mean diFerence post-treatment using this scale favored the
attention control (MD 0.72, 95% CI -5.40 to 6.84; n = 80; P = 0.82; very
low-certainty evidence) (Figure 17; Analysis 6.3) but the eFect was
small and chance cannot be ruled out (Blanchard 1992a; Blanchard
1992b).
 
Figure 17.   Forest plot of comparison: 6 Multicomponent Psychological Intervention (with Biofeedback) versus
Attention control, outcome: 6.3 Abdominal Pain.
 
Biofeedback versus relaxation training
DeRoo 1988 used a 0 to 4-point scale to measure abdominal pain
(no pain to severe pain) and reported that there was no diFerence
between groups in abdominal pain (the trial authors only reported
statistical tests, not summary eFect sizes).
Depression
Outcome-level data on depression was reported in four of the
eight included studies (Blanchard 1992a; Blanchard 1992b, DeRoo
1988; Dobbin 2013). These studies reported on results from four
comparisons as delineated below, grouped by comparison.
Biofeedback versus hypnotherapy
Dobbin 2013 used the Hospital Anxiety and Depression Scale
(HADS) to report the impact of the intervention on depression. They
reported 12-week primary endpoint depression subscores of 4.9 for
biofeedback and 5.9 for hypnotherapy. Although the MD favored
biofeedback, the diFerence was small and the eFect of chance
cannot be ruled out (MD -1.00, 95% CI -3.18 to 1.18; n = 61; P = 0.37;
low-certainty evidence) (Figure 18; Analysis 3.2)
 
Figure 18.   Forest plot of comparison: 3 Biofeedback versus Hypnotherapy, outcome: 3.2 Depression.
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Multi-component psychological intervention (with biofeedback)
versus no-treatment control
Blanchard 1992a and Blanchard 1992b both used the Beck
Depression Inventory. In pooled analysis of these two trials, the
MD favored the multi-component psychological intervention (with
biofeedback) group compared to no-treatment control (MD -3.80,
95% CI -6.90 to -0.69; n = 82; P = 0.02, I2 = 0%; very low-certainty
evidence) (Figure 19; Analysis 5.12).
 
Figure 19.   Forest plot of comparison: 5 Multicomponent Psychological Intervention (with Biofeedback) versus No-
treatment control, outcome: 5.12 Depression.
 
Multi-component psychological intervention (with biofeedback)
versus attention control
Blanchard 1992a and Blanchard 1992b both used the Beck
Depression Inventory. In pooled analysis of these two trials, the MD
favored the attention control group (MD 0.13, 95% CI -2.73 to 2.98;
n = 80; P = 0.84, I2 = 0%; very low-certainty evidence) (Figure 20;
Analysis 6.4).
 
Figure 20.   Forest plot of comparison: 6 Multicomponent Psychological Intervention (with Biofeedback) versus
Attention control, outcome: 6.4 Depression.
 
Biofeedback versus relaxation training
DeRoo 1988 reported depression scores from a depression
subcategory of the HCL 90-R. They reported that all groups had an
improvement from baseline to post-treatment, but the between-
group comparisons were similar (P = 0.60). The trial authors did not
report group-level eFect sizes or within-group P values.
Anxiety
Outcome level data on anxiety was reported in four of the
eight included studies (Blanchard 1992a; Blanchard 1992b, DeRoo
1988; Dobbin 2013). These studies reported on results from four
comparisons as delineated below, grouped by comparison
Biofeedback versus hypnotherapy
Dobbin 2013 used the HADS to report the impact of the intervention
on anxiety. They reported 12-week primary endpoint anxiety
subscores of 9.8 for biofeedback and 9.1 for hypnotherapy (MD 0.70,
95% CI -1.68 to 3.08; n = 61; P = 0.56; low-certainty evidence) (Figure
21; Analysis 3.3).
 
Figure 21.   Forest plot of comparison: 3 Biofeedback versus Hypnotherapy, outcome: 3.3 Anxiety.
 
Multi-component psychological intervention (with biofeedback)
versus no-treatment control
Blanchard 1992a and Blanchard 1992b both used the State-Trait
Anxiety Inventory. In a pooled analysis of these two trials, the
MD for state anxiety favored the multi-component psychological
intervention (with biofeedback) group compared to no-treatment
control (MD -8.63, 95% CI -12.48 to -4.77; n = 82; P < 0.01, I2 = 0%; very
low-certainty evidence) (Figure 22; Analysis 5.13). The MD for trait
anxiety favored the multi-component psychological intervention
(with biofeedback) group compared to no-treatment control (MD
-3.98, 95% CI -7.96 to -0.00; n = 82; P = 0.05, I2 = 51%; very low-
certainty evidence) (Figure 23; Analysis 5.14).
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Figure 22.   Forest plot of comparison: 5 Multicomponent Psychological Intervention (with Biofeedback) versus No-
treatment control, outcome: 5.13 Anxiety - State.
 
 
Figure 23.   Forest plot of comparison: 5 Multicomponent Psychological Intervention (with Biofeedback) versus No-
treatment control, outcome: 5.14 Anxiety - Trait.
 
Multi-component psychological intervention (with biofeedback)
versus attention control
Blanchard 1992a and Blanchard 1992b both used the State-Trait
Anxiety Inventory. In pooled analysis of these two trials, the
MD for state anxiety favored the multi-component psychological
intervention (with biofeedback) group compared to attention
control, although the diFerence was small and the eFects of chance
cannot be ruled out (MD -0.74, 95% CI -5.38 to 3.89; n = 82; P = 0.75,
I2 = 0%; very low-certainty evidence) (Figure 24; Analysis 6.5).
 
Figure 24.   Forest plot of comparison: 6 Multicomponent Psychological Intervention (with Biofeedback) versus
Attention control, outcome: 6.5 Anxiety - State.
 
For trait anxiety, the MD favored the attention control, although the
diFerence was small and the eFects of chance cannot be ruled out
(MD 2.05, 95% CI -2.05 to 6.57; n = 82; P = 0.38, I2 = 50%; very low-
certainty evidence) (Figure 25; Analysis 6.6).
 
Figure 25.   Forest plot of comparison: 6 Multicomponent Psychological Intervention (with Biofeedback) versus
Attention control, outcome: 6.6 Anxiety - Trait.
 
Biofeedback versus relaxation training
DeRoo 1988 reported anxiety scores from an anxiety subcategory of
the HCL 90-R. They reported that all groups had improvement pre/
post-treatment (P < 0.007) but that the between group comparisons
were equivalent. The trial authors did not provide group-level eFect
sizes or specific between- and within-group P values).
Sensitivity Analyses
We conducted sensitivity analyses in order to determine the
role that meta-analysis model (random versus fixed) and missing
outcome data played on our primary outcome results. Because
of the identical nature of the intervention, control, and outcome
measure, we chose to meta-analyze the following comparisons
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using a fixed-eFect model as a primary analysis: multi-component
psychological intervention (with biofeedback) versus no-treatment
control and multi-component psychological intervention (with
biofeedback) versus attention control. We then conducted
sensitivity analysis using a random-eFects model (Analysis 5.2
for symptom improvement; Analysis 5.8 for clinical response).
When using a random-eFects model, the eFect size was marginally
smaller, but still favored biofeedback and the eFect estimate
survived the sensitivity analysis (Analysis 5.8).
As there were some missing outcome data in two of the three meta-
analyzed trials for our primary outcome of clinical improvement
(Blanchard 1992b; NeF 1987), we also conducted a sensitivity
analysis using GRADE guidance for handling missing outcome
data (Guyatt 2017). For the dichotomous outcome of clinical
responder in the comparison of multi-component psychological
intervention (with biofeedback) versus no-treatment control, the
eFect decreased as we increased the strictness of the assumptions.
At a 2:1 ratio, we assumed that all participants with missing
outcome data in the biofeedback group had been non-responders.
This assumption led to a lower eFect estimate, but still favored
biofeedback and the eFect estimate survived the sensitivity
analysis (Analysis 5.10).
We carried out the missing data sensitivity analysis for the
continuous outcome 'symptom improvement', in the comparison
of multi-component psychological intervention (with biofeedback)
versus no-treatment control. In this analysis, the eFect decreased
as increasing levels of sensitivity assumptions were made.
However, even with the strictest assumptions, the eFect estimate
still favored biofeedback and the eFect estimate survived the
sensitivity analysis (Analysis 5.6).
demonstrated that the benefit was not robust to all assumptions.
With the strictest assumption, the eFect decreased and the eFects
of chance could not be ruled out (Analysis 3.7).
D I S C U S S I O N
Summary of main results
We identified eight small randomized trials (n = 300) of
biofeedback that met our inclusion criteria. Overall, low to very
low-certainty evidence demonstrated no benefit to a moderate
clinically important benefit of biofeedback versus non-active
and active (e.g. hypnotherapy) controls. One study suggested
a moderate clinically important benefit of electrocutaneous
resistance biofeedback when used in combination with standard
IBS treatment, when compared to both standard therapy alone
and standard therapy with sham biofeedback (Trembach 2009).
We noted a small, but clinically important, benefit with heart rate
variability biofeedback when compared to hypnotherapy (Dobbin
2013). We observed a small benefit for biofeedback compared to
counseling, but could not rule out the eFect of chance (Thompson
2010; Leahy 1997). We noted a moderate clinically important
benefit for a multi-component psychological intervention, which
included thermal biofeedback, compared to no-treatment control
(Blanchard 1992a). However, we could not rule out the eFect
of chance when this intervention was compared to an attention
control (Blanchard 1992b). Rectosigmoidal biofeedback showed
less clinical benefit than relaxation control, but we could not rule
out the eFect of chance (DeRoo 1988).
Of the eight included studies, only one formally measured quality
of life (Thompson 2010). In comparing heart rate variability
biofeedback to a cognitive therapy active control, both the
biofeedback and cognitive therapy groups showed improvement in
their IBS-IS score but the trial authors did not note any between-
group diFerences or report any outcome data.
Overall completeness and applicability of evidence
Participants were more likely to be female, and clustered in age
near 40 (though many trials only reported mean age). The recruiting
for these trials also suggests that they were largely limited to people
who already had access to medical care. As such, the applicability of
these results to children, the elderly, and underserved populations
is uncertain.
The AAPB defines biofeedback as “a process that enables an
individual to learn how to change physiological activity for the
purposes of improving health and performance”(AAPB 2016).
Germane to this definition is that the use of an appropriate
biofeedback intervention involves a change in physiological
activity (e.g. change in heart rate variability, skin temperature, etc.),
and that such change may improve health outcomes. In the studies
included in our systematic review, the majority of researchers did
not report baseline physiological measurements consistent with
autonomic nervous system (ANS) functioning, nor did they report
physiological response or non-response to biofeedback treatment.
According to the autonomic nervous system hypothesis of IBS,
individuals with IBS are more prone towards increased sympathetic
and decreased parasympathetic nervous system activity (Manabe
2009). Since these studies did not report baseline measures of
physiological activity indicative of autonomic nervous system
function, it is unclear whether or not the individuals included in
these studies would have been considered ANS-normal or ANS-
abnormal at the start of the treatment intervention. In addition,
while these studies reported on clinical response by the end of
the intervention period, they did not clearly report physiological
response. Finally, the durability of physiological change (e.g.
sustainability of change over time), which is an important part
of clinical biofeedback, was not reported in these studies. These
concerns collectively speak to the applicability of this evidence
to real world biofeedback, in which physiological baseline and
response to therapy is an important component of treatment
(Schartz 2003). While reporting on results of an IBS cohort
regardless of physiologic status limits selection bias, additional
reporting on physiologic responders as a subgroup may more
appropriately mimic real world practice.
Quality of the evidence
There are large non-specific eFects of intervention (i.e. placebo
eFects) in IBS studies in general, especially when the intervention
arm is complex and the provider-patient interaction is substantial,
such as with biofeedback (Kaptchuk 2008). Additionally, blinding
of intervention is diFicult with biofeedback, and IBS outcome
measures are subjectively reported. There is meta-epidemiologic
evidence to suggest large biases in unmasked trials when subjective
outcome measures are used (Wood 2008).
For these and other reasons, as discussed in the Characteristics
of included studies tables below, we believe that all eight of our
included studies were high or unclear in their risk of bias.
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We used GRADE criteria to assess the overall certainty of
evidence for all comparisons for the primary outcomes, as well
as the secondary outcomes of adverse events, serious adverse
events, pain, depression, and anxiety, when possible. All GRADE
assessments are reported in the 'Summary of findings' tables.
GRADE evaluations ranged from very low to low, indicating that we
have very little certainty in the eFect estimates for some outcomes,
and for others our certainty is very limited.
For the primary outcome of clinical/global improvement, we gave
a low-certainty rating to the comparison of a multi-component
psychological intervention (with biofeedback) versus no-treatment
control. The estimated eFect was an improvement of 30 points
on the CPSR scale and a risk ratio of 2.12 for clinical response,
favoring biofeedback. When we compared the same biofeedback
intervention to an attention control, we found the estimated eFect
of a 4-point improvement on the CPSR scale and a risk ratio of 1.10
for clinical response to be very low certainty as well. We had low
certainty in the estimated improvement of 59 points on the IBS-
SSS scale when we compared biofeedback to hypnotherapy and
low certainty in the 7-point CPSR improvement when we compared
biofeedback to counseling. We had very low certainty in the small
estimated mean diFerence of 0.30 in symptom severity, favoring the
relaxation control, when we compared rectosigmoidal biofeedback
to a relaxation control. Finally, we had very low certainty in the
estimated risk ratio of 4.20, favoring biofeedback, for clinical
response when we compared 'biofeedback with standard therapy'
to standard therapy alone. We also had low certainty in the risk ratio
of 2.33 when we compared 'biofeedback with standard therapy'
with 'sham biofeedback and standard therapy'.
Potential biases in the review process
While we attempted to locate each of the articles identified in our
literature review, there were nine studies that, despite considerable
eFort, we were unable to locate for the review and could not assess
for potential inclusion. It is possible that one or more of these
studies could have led to a change in our conclusion.
Our approach to assessment of performance bias is arguably
potentially overly conservative for active control comparisons and
potentially under conservative for attention control comparisons.
However, this decision was based on published literature on non-
specific eFects in IBS using elaborate 'interventions' (Kaptchuk
2008), which we argue is appropriate in an elaborate modality such
as biofeedback, We were consistent in this approach across the
studies we evaluated. Additionally, pragmatically because it meant
we would err on assessing performance bias as unclear when others
might consider it low for active control comparisons, this would
lead to a more conservative estimation in our a priori sensitivity
analyses based on low versus high/unclear risk of bias studies.
Conversely, for attention control comparisons, the determination
between high or unclear would not impact on sensitivity analysis
as high and unclear studies would be grouped together anyway.
While other people may disagree, our approach was applied
consistently across studies, was based on published literature, and
pragmatically led to a more conservative methodology.
We followed consensus guidelines and did not conduct a formal
publication bias assessment because we had less than 10 trials per
outcome (Sterne 2011).
Agreements and disagreements with other studies or
reviews
We are unaware of other systematic reviews of this subject.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is not currently enough evidence to assess whether
biofeedback interventions are eFective for controlling symptoms
of irritable bowel syndrome (IBS). Some positive results have been
reported in small studies. While the eFect estimates suggests a
benefit of biofeedback when used as part of a multi-component
psychological intervention, compared to a no-treatment control,
for clinical symptoms, depression, and anxiety, in the context of
the very low quality of evidence we cannot be certain if there
is an eFect or not. Compared to hypnotherapy, biofeedback may
reduce IBS symptoms. When compared to counseling, biofeedback
appears not to reduce overall IBS symptoms or abdominal pain.
When biofeedback is used with standard therapy and compared
to standard therapy alone or with sham biofeedback, biofeedback
may lead to overall symptom reduction.
Implications for research
Upon review of the available randomized clinical trial evidence on
biofeedback for IBS, we noted several areas of deficit that would
benefit from targeted future research, as delineated below.
1. Utilization of active control groups that use high provider-
patient interaction, in an attempt to balance non-specific eFects
of intervention between groups.
2. Implementation of commonly used outcome measures (e.g. IBS-
symptom severity score [IBS-SSS]) that are most important to
people with IBS, as well as historical outcome measures (e.g.
composite primary symptom reduction score [CPSR]) to allow
for meta-analysis with previous studies.
3. Larger trials enrolling 100 or more participants.
4. Future trials should focus on biofeedback forms showing
preliminary benefit, as identified as in this review (e.g. heart rate
variability).
5. No identified trials compared diFerent modalities of
biofeedback in head to head comparisons; such trial design
would help inform if eFicacy should be best viewed as a class
eFect or if specific biofeedback types (e.g. heart rate variability
versus skin conductance) show superiority or non-inferiority.
6. Whilst we do value multi-component intervention research,
such designs make attribution of eFect to biofeedback,
specifically, impossible. Future research in this early phase of
the evidence base should focus on eFicacy of the individual
biofeedback interventions.
7. Future studies should measure baseline autonomic nervous
system function with validated measures and methodologies,
with the goal of classifying participants as autonomic nervous
system (ANS)-normal or ANS-abnormal.
8. Future studies should measure post-treatment ANS function
and compare these measurements with baseline ANS measures,
with the aim of classifying participants as physiological
responders and non-responders to biofeedback treatment.
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9. Future studies should aim to determine the durability of
physiological change over-time and to correlate this change
with any improvements (transient or stable) in IBS symptoms.
10.Studies should closely examine the correlation between IBS
symptom improvement and physiological response and non-
response to biofeedback treatment with the aim of further
clarifying placebo eFects versus true eFects of treatment.
11.Future studies should closely examine medication status of
the participants with respect to medications which may alter
ANS function, thus potentially confounding the eFects of
biofeedback treatment.
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Characteristics of included studies [ordered by study ID]
 
Methods 3 arm RCT
Participants n = 30 adult participants with IBS (unclear what percentage had which IBS subtype); 10 participants in
each treatment group; age range 23-76; USA
Interventions (1) multi-component psychological treatment which included thermal biofeedback
(2) 'pseudomeditation' attention control
Blanchard 1992a 
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(3) symptom monitoring
Outcomes Assessments at baseline and after 8 weeks of treatment with a global assessment scale.
Secondary outcome measures included assessment of abdominal pain, depression, and anxiety.
Notes Unclear funding source.
Please note that this study and Blanchard 1992b are separate studies reported in the same publication.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Unclear risk There appears to be blinding between the active and attention control groups
for participants, but not for the personnel or for the wait-list control.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Outcome assessors were the participants. Active group and attention control
were likely to have been adequately blinded, and any comparison between
these groups would be low risk. However, any comparison with the wait-list




Low risk No missing outcome data
Selective reporting (re-
porting bias)
Low risk Outcomes reported match methods




Methods 3 arm RCT comparing 8 weeks of skin conductance biofeedback with stress reduction techniques to an
attention control and no-treatment control.
Participants n = 92 adult participant with IBS (28 IBS-D, 23 IBS-C, 41 IBS-M), average age = 43.4, USA
Interventions (1) multi-component psychological treatment, which included thermal biofeedback (n = 31)
(2) 'pseudomeditation' attention control (n = 30)
(3) symptom monitoring (n = 31)
Outcomes Assessments at baseline and after 8 weeks of treatment with a global symptom assessment scale.
Secondary outcome measures included assessment of abdominal pain, depression, and anxiety.
Notes Unclear funding source
Blanchard 1992b 
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Please note that this study and Blanchard 1992a are separate studies reported in the same publication.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Unclear risk Not clear if there was blinding regarding which of the active groups was the
group of interest.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





High risk > 10% missing data
Selective reporting (re-
porting bias)
Low risk outcomes reported match methods




Methods 3 arm RCT compared biofeedback (n = 5) with a relaxation control (n = 5) and a sham biofeedback con-
trol (n = 3). While the text is unclear, it appears only the biofeedback arm and the relaxation arm were
truly randomized and so the third arm was not included in analysis.
Participants 13 adult men and women in US with IBS-D, average age of 41.7
Interventions Biofeedback used rectosigmoidal manometry as teaching tool for 5 to 8 1-hour sessions.
Outcomes Assessment by scale at baseline and after 5 to 8 sessions. Secondary outcome measures assessed stool
frequency, abdominal pain, anxiety, and depression
Notes Not clearly reported how many participants finished the trial and were assessed. This was a disserta-
tion. Unclear funding source.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details on method
Allocation concealment
(selection bias)
Unclear risk Not discussed
DeRoo 1988 
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High risk Not discussed, likely unblinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk No attrition
Selective reporting (re-
porting bias)
Low risk All outcomes stated in methods are reported




Methods A 12-week unblinded RCT comparing biofeedback (n=31) and hypnotherapy (n=30) in the management
of IBS.
Participants 61 women, age 18-60 with a diagnosis of IBS. Trial was in Scotland.
Interventions Biofeedback measured heart rate variability during three 1-hour sessions. Participants also used tech-
niques learned during sessions daily at home.
Outcomes IBS-SSS and HADS at baseline and at 12 weeks
Notes There was no untreated control condition.
Unclear funding source
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomization
Allocation concealment
(selection bias)





Unclear risk Since both groups got active intervention, should not be materially biased
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk See above, outcomes were measured by participant
Incomplete outcome data
(attrition bias) 
High risk Dropouts exceeded 10%
Dobbin 2013 
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Low risk All outcomes assessed are reported




Methods RCT comparing 4 sessions of biofeedback to counseling in management of IBS symptoms
Participants 21 adult UK residents with IBS (unclear what percentage had which IBS subtype, or how many partici-
pants were in each treatment group).
Interventions Electrocutaneous monitoring with video feedback
Outcomes Participants were assessed using a scale developed by the authors at baseline and after the interven-
tion
Notes Trial reported as abstract only.
Unclear funding source
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomization not described
Allocation concealment
(selection bias)





High risk Not blinded. Each participant went through biofeedback in pilot, so would
have known if in active treatment group
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Only reported as abstract
Selective reporting (re-
porting bias)
Unclear risk Only reported as abstract
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Methods RCT compared biofeedback (n = 10) with untreated controls (n = 9) in the management of IBS
Participants 19 US adults with IBS (7 IBS-D, 8 IBS-C, 4 IBS-M), average age 41 years, 6 male/14 female
Interventions 12 treatments of thermal biofeedback during relaxation training
Outcomes Assessment of IBS symptoms and abdominal pain via self-developed scale at baseline and 2 weeks
post-treatment
Notes Assessments were over a daily average of the 2 weeks post-assessment, not a single day's symptoms.
Unclear funding source
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomization procedure not described
Allocation concealment
(selection bias)





High risk Unblinded, controls were untreated
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Only 1 dropout
Selective reporting (re-
porting bias)
Unclear risk It appears the outcomes chosen for the included trial (study 2 in the published
report) were different from the outcome used in study 1, which was the pilot
study for pilot 2. It is unclear why this change was made.




Methods RCT comparing biofeedback (n = 19) and cognitive behavioral therapy (n = 18) for symptom manage-
ment in IBS over an 8-week period.
Participants 37 adults with IBS (11 IBS-D, 15 IBS-C, 11 IBS-M), average age 54, 32 female/5 male; USA
Interventions 11 weekly treatments with biofeedback via heart rate variability and skin temperature
Outcomes CFSBD was the key IBS specific outcome measure. A CPSR score was also calculated.
Secondary outcome measures included IBS Impact Score and abdominal pain reporting.
Notes Reporting on outcomes was unclear regarding the intervals of measurement. This was a dissertation.
Thompson 2010 
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Unclear funding source
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number generator
Allocation concealment
(selection bias)





Unclear risk Appears to have been unblinded, but controls were active treatment group
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk 21% dropout rate. Dropouts were similar in active treatment groups, but rea-
sons were not provided.
Selective reporting (re-
porting bias)
Low risk Reported outcomes match methods




Methods 3 arm RCT comparing 'standard therapy' (fiber and medication) (n =10) to standard therapy plus
biofeedback (n = 10) and what appears to be a sham biofeedback arm plus standard therapy (n =10 ).
Participants 30 Russian women aged 18-35 with non-diarrhea IBS
Interventions Up to 6 months of biofeedback treatment using electrocutaneous resistance sensors
Outcomes Constipation, abdominal pain, stool consistency (using the Brisol Stool Scale), and clinical improve-
ment.
Assessed at baseline, 1 month, and 6 months.




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Procedure not described
Trembach 2009 
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Allocation concealment
(selection bias)





High risk Unblinded trial
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk No dropouts
Selective reporting (re-
porting bias)
Unclear risk Protocol not available
Other bias Low risk None noted
Trembach 2009  (Continued)
RCT = randomized controlled trial; IBS = irritable bowel syndrome; IBS-C = IBS-constipation predominant; IBS-D = IBS-diarrhea
predominant; IBS-M = IBS-mixed; IBS-SSS = IBS symptom severity score; HADS = hospital anxiety and depression scale; CFSBD = cognitive
scale for functional bowel disorders; CPSR = composite primary symptom reduction score.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ahadi 2014 Not an RCT
Bergeron 1983 Not truly randomized
Bleijenberg 1994 Not IBS
Boyce 2003 Not biofeedback
Folgar 1995 Unable to acquire
Fu 2014 Unable to acquire
Grey 1983 Wrong study type - not randomized
Ryan 2004 Not exclusively IBS patients. Mixed groups of multiple functional bowel disorders. Results not
differentiated by disorder type.
Singles 1989 Wrong population, not IBS
van der Plas 1994 Wrong population, not IBS
RCT = randomized controlled trial; IBS = irritable bowel syndrome
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D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Biofeedback plus standard therapy versus standard therapy





Statistical method Effect size
1 Clinical Response 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.2 [1.40, 12.58]
2 Abdominal Pain (4 weeks) 1 20 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Abdominal Pain (6 months) 1 20 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 1.1.   Comparison 1 Biofeedback plus standard
therapy versus standard therapy, Outcome 1 Clinical Response.





Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Trembach 2009 10/10 2/10 100% 4.2[1.4,12.58]
   
Total (95% CI) 10 10 100% 4.2[1.4,12.58]
Total events: 10 (Biofeedback + standard therapy), 2 (Standard therapy)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.56(P=0.01)  
Biofeedback + standard therapy 1000.01 100.1 1 Standard therapy
 
 
Analysis 1.2.   Comparison 1 Biofeedback plus standard therapy
versus standard therapy, Outcome 2 Abdominal Pain (4 weeks).
Study or subgroup Biofeedback +
standard therapy
Standard therapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Trembach 2009 10 0 (0) 10 0.6 (0)   Not estimable
   
Total *** 10   10   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Biofeedback + standard therapy 10050-100 -50 0 Standard therapy
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Analysis 1.3.   Comparison 1 Biofeedback plus standard therapy
versus standard therapy, Outcome 3 Abdominal Pain (6 months).
Study or subgroup Biofeedback +
standard therapy
Standard therapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Trembach 2009 10 0.6 (0) 10 1.2 (0)   Not estimable
   
Total *** 10   10   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Biofeedback + standard therapy 10050-100 -50 0 Standard therapy
 
 
Comparison 2.   Biofeedback plus standard therapy versus sham biofeedback plus standard therapy





Statistical method Effect size
1 Clinical Response 1 20 Risk Ratio (M-H, Fixed, 95% CI) 2.33 [1.13, 4.80]
2 Abdominal Pain (4 weeks) 1 20 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Abdominal Pain (6 months) 1 20 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 2.1.   Comparison 2 Biofeedback plus standard therapy versus
sham biofeedback plus standard therapy, Outcome 1 Clinical Response.






Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Trembach 2009 10/10 4/10 100% 2.33[1.13,4.8]
   
Total (95% CI) 10 10 100% 2.33[1.13,4.8]
Total events: 10 (Biofeedback + standard therapy), 4 (Sham biofeedback +
standard therapy)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=2.3(P=0.02)  
Biofeedback + standard therapy 1000.01 100.1 1 Sham biofeedback + standard therapy
 
 
Analysis 2.2.   Comparison 2 Biofeedback plus standard therapy versus sham
biofeedback plus standard therapy, Outcome 2 Abdominal Pain (4 weeks).




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Trembach 2009 10 0 (0) 10 0.6 (0)   Not estimable
   
Biofeedback + standard therapy 10050-100 -50 0 Sham biofeedback + standard ther-
apy
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Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Total *** 10   10   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  




Analysis 2.3.   Comparison 2 Biofeedback plus standard therapy versus sham
biofeedback plus standard therapy, Outcome 3 Abdominal Pain (6 months).




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Trembach 2009 10 0 (0) 10 1 (0)   Not estimable
   
Total *** 10   10   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  




Comparison 3.   Biofeedback versus hypnotherapy





Statistical method Effect size
1 Symptom Improvement (measured by IBS-
SSS)
1 61 Mean Difference (IV, Fixed, 95% CI) -58.8 [-109.11,
-8.49]
2 Depression 1 61 Mean Difference (IV, Fixed, 95% CI) -1.0 [-3.18, 1.18]
3 Anxiety 1 61 Mean Difference (IV, Fixed, 95% CI) 0.70 [-1.68, 3.08]
4 Symptom Improvement (measured by IBS-
SSS) - Sensitivity Analysis Strategy 1
1 76 Mean Difference (IV, Fixed, 95% CI) -47.97 [-93.09,
-2.85]
5 Symptom Improvement (measured by IBS-
SSS) - Sensitivity Analysis Strategy 2
1 76 Mean Difference (IV, Fixed, 95% CI) -58.8 [-103.92,
-13.68]
6 Symptom Improvement (measured by IBS-
SSS) - Sensitivity Analysis Strategy 3
1 76 Mean Difference (IV, Fixed, 95% CI) -47.97 [-93.09,
-2.85]
7 Symptom Improvement (measured by IBS-
SSS) - Sensitivity Analysis Strategy 4
1 76 Mean Difference (IV, Fixed, 95% CI) -35.59 [-80.71, 9.53]
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Analysis 3.1.   Comparison 3 Biofeedback versus hypnotherapy,
Outcome 1 Symptom Improvement (measured by IBS-SSS).
Study or subgroup Biofeedback Hypnotherapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Dobbin 2013 31 -116.8
(99.3)
30 -58 (101.1) 100% -58.8[-109.11,-8.49]
   
Total *** 31   30   100% -58.8[-109.11,-8.49]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.29(P=0.02)  
Biofeedback 10050-100 -50 0 Hypnotherapy
 
 
Analysis 3.2.   Comparison 3 Biofeedback versus hypnotherapy, Outcome 2 Depression.
Study or subgroup Biofeedback Hypnotherapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Dobbin 2013 31 4.9 (3.7) 30 5.9 (4.9) 100% -1[-3.18,1.18]
   
Total *** 31   30   100% -1[-3.18,1.18]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.9(P=0.37)  
Biofeedback 10050-100 -50 0 Hypnotherapy
 
 
Analysis 3.3.   Comparison 3 Biofeedback versus hypnotherapy, Outcome 3 Anxiety.
Study or subgroup Biofeedback Hypnotherapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Dobbin 2013 31 9.8 (4.1) 30 9.1 (5.3) 100% 0.7[-1.68,3.08]
   
Total *** 31   30   100% 0.7[-1.68,3.08]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.58(P=0.56)  
Biofeedback 10050-100 -50 0 Hypnotherapy
 
 
Analysis 3.4.   Comparison 3 Biofeedback versus hypnotherapy, Outcome 4
Symptom Improvement (measured by IBS-SSS) - Sensitivity Analysis Strategy 1.
Study or subgroup Biofeedback Hypnotherapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Dobbin 2013 38 -106 (99.6) 38 -58 (101.1) 100% -47.97[-93.09,-2.85]
   
Total *** 38   38   100% -47.97[-93.09,-2.85]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.08(P=0.04)  
Biofeedback 10050-100 -50 0 Hypnotherapy
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Analysis 3.5.   Comparison 3 Biofeedback versus hypnotherapy, Outcome 5
Symptom Improvement (measured by IBS-SSS) - Sensitivity Analysis Strategy 2.
Study or subgroup Biofeedback Hypnotherapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Dobbin 2013 38 -116.8
(99.6)
38 -58 (101.1) 100% -58.8[-103.92,-13.68]
   
Total *** 38   38   100% -58.8[-103.92,-13.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.55(P=0.01)  
Biofeedback 10050-100 -50 0 Hypnotherapy
 
 
Analysis 3.6.   Comparison 3 Biofeedback versus hypnotherapy, Outcome 6
Symptom Improvement (measured by IBS-SSS) - Sensitivity Analysis Strategy 3.
Study or subgroup Biofeedback Hypnotherapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Dobbin 2013 38 -106 (99.6) 38 -58 (101.1) 100% -47.97[-93.09,-2.85]
   
Total *** 38   38   100% -47.97[-93.09,-2.85]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.08(P=0.04)  
Biofeedback 10050-100 -50 0 Hypnotherapy
 
 
Analysis 3.7.   Comparison 3 Biofeedback versus hypnotherapy, Outcome 7
Symptom Improvement (measured by IBS-SSS) - Sensitivity Analysis Strategy 4.
Study or subgroup Biofeedback Hypnotherapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI




Total *** 38   38   100% -35.59[-80.71,9.53]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.55(P=0.12)  
Biofeedback 10050-100 -50 0 Hypnotherapy
 
 
Comparison 4.   Biofeedback versus Counseling





Statistical method Effect size
1 Symptom Improvement (measured
by CPSR)
1 29 Mean Difference (IV, Fixed, 95% CI) 7.03 [-51.07, 65.13]
2 Clinical Response (complete case) 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.48, 2.45]
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Statistical method Effect size
3 Adverse Events 1 29 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.12, 0.12]
4 Serious Adverse Events 1 29 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.12, 0.12]
5 Abdominal Pain 1 29 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.43, 0.52]
 
 
Analysis 4.1.   Comparison 4 Biofeedback versus Counseling,
Outcome 1 Symptom Improvement (measured by CPSR).
Study or subgroup Biofeedback Counseling Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Thompson 2010 15 38.5 (81.2) 14 31.5 (78.4) 100% 7.03[-51.07,65.13]
   
Total *** 15   14   100% 7.03[-51.07,65.13]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.24(P=0.81)  
Biofeedback 10050-100 -50 0 Counseling
 
 
Analysis 4.2.   Comparison 4 Biofeedback versus Counseling, Outcome 2 Clinical Response (complete case).
Study or subgroup Biofeedback Counseling Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Thompson 2010 7/15 6/14 100% 1.09[0.48,2.45]
   
Total (95% CI) 15 14 100% 1.09[0.48,2.45]
Total events: 7 (Biofeedback), 6 (Counseling)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.84)  
Biofeedback 1000.01 100.1 1 Counseling
 
 
Analysis 4.3.   Comparison 4 Biofeedback versus Counseling, Outcome 3 Adverse Events.
Study or subgroup Biofeedback Counseling Risk Difference Weight Risk Difference
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Thompson 2010 0/15 0/14 100% 0[-0.12,0.12]
   
Total (95% CI) 15 14 100% 0[-0.12,0.12]
Total events: 0 (Biofeedback), 0 (Counseling)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Biofeedback 10.5-1 -0.5 0 Counseling
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Analysis 4.4.   Comparison 4 Biofeedback versus Counseling, Outcome 4 Serious Adverse Events.
Study or subgroup Biofeedback Counseling Risk Difference Weight Risk Difference
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Thompson 2010 0/15 0/14 100% 0[-0.12,0.12]
   
Total (95% CI) 15 14 100% 0[-0.12,0.12]
Total events: 0 (Biofeedback), 0 (Counseling)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Biofeedback 10.5-1 -0.5 0 Counseling
 
 
Analysis 4.5.   Comparison 4 Biofeedback versus Counseling, Outcome 5 Abdominal Pain.
Study or subgroup Biofeedback Counseling Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Thompson 2010 15 0.7 (0.7) 14 0.7 (0.6) 100% 0.04[-0.43,0.52]
   
Total *** 15   14   100% 0.04[-0.43,0.52]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
Biofeedback 10050-100 -50 0 Counseling
 
 
Comparison 5.   Multi-component psychological intervention (with biofeedback) versus no-treatment control





Statistical method Effect size
1 Symptom Improvement (measured by
CPSR)
3 101 Mean Difference (IV, Fixed, 95% CI) 30.34 [8.47, 52.21]
2 Symptom Improvement (measured by
CPSR) - Sensitivity Analysis - Random Effects
3 101 Mean Difference (IV, Random, 95%
CI)
30.34 [8.47, 52.21]
3 Symptom Improvement (measured by
CPSR) - Sensitivity Analysis Strategy 1
3 117 Mean Difference (IV, Fixed, 95% CI) 27.02 [6.80, 47.24]
4 Symptom Improvement (measured by
CPSR) - Sensitivity Analysis Strategy 2
3 117 Mean Difference (IV, Fixed, 95% CI) 28.75 [8.52, 48.97]
5 Symptom Improvement (measured by
CPSR) - Sensitivity Analysis Strategy 3
3 117 Mean Difference (IV, Fixed, 95% CI) 25.94 [5.71, 46.16]
6 Symptom Improvement (measured by
CPSR) - Sensitivity Analysis Strategy 4
3 117 Mean Difference (IV, Fixed, 95% CI) 20.85 [0.63, 41.08]
7 Clinical Response (complete case) 3 101 Risk Ratio (M-H, Fixed, 95% CI) 2.12 [1.24, 3.62]
8 Clinical Response - Sensitivity Analysis -
Random Effects
3 101 Risk Ratio (M-H, Random, 95% CI) 1.95 [1.14, 3.32]
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Statistical method Effect size
9 Clinical Response -Sensitivity Analysis -
Missing Outcome Data - 1.5:1
3 117 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [1.17, 3.13]
10 Clinical Response -Sensitivity Analysis -
Missing Outcome Data - 2:1
3 117 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [1.08, 2.95]
11 Abdominal Pain 2 82 Mean Difference (IV, Fixed, 95% CI) -1.40 [-7.54, 4.74]
12 Depression 2 82 Mean Difference (IV, Fixed, 95% CI) -3.80 [-6.90, -0.69]
13 Anxiety - State 2 82 Mean Difference (IV, Fixed, 95% CI) -8.63 [-12.48,
-4.77]
14 Anxiety - Trait 2 82 Mean Difference (IV, Fixed, 95% CI) -3.98 [-7.96, -0.00]
 
 
Analysis 5.1.   Comparison 5 Multi-component psychological intervention (with biofeedback)
versus no-treatment control, Outcome 1 Symptom Improvement (measured by CPSR).




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 45.2 (59.3) 10 9.5 (53.3) 19.59% 35.7[-13.72,85.12]
Blanchard 1992b 31 32.4 (63.2) 31 6.4 (57) 53.3% 26[-3.96,55.96]
NeF 1987 10 50.4 (47.9) 9 15.4 (45.5) 27.11% 35[-7.01,77.01]
   
Total *** 51   50   100% 30.34[8.47,52.21]
Heterogeneity: Tau2=0; Chi2=0.17, df=2(P=0.92); I2=0%  
Test for overall effect: Z=2.72(P=0.01)  
MCPI with biofeedback 10050-100 -50 0 no-treatment control
 
 
Analysis 5.2.   Comparison 5 Multi-component psychological intervention (with biofeedback) versus no-
treatment control, Outcome 2 Symptom Improvement (measured by CPSR) - Sensitivity Analysis - Random E:ects.




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Blanchard 1992a 10 45.2 (59.3) 10 9.5 (53.3) 19.59% 35.7[-13.72,85.12]
Blanchard 1992b 31 32.4 (63.2) 31 6.4 (57) 53.3% 26[-3.96,55.96]
NeF 1987 10 50.4 (47.9) 9 15.4 (45.5) 27.11% 35[-7.01,77.01]
   
Total *** 51   50   100% 30.34[8.47,52.21]
Heterogeneity: Tau2=0; Chi2=0.17, df=2(P=0.92); I2=0%  
Test for overall effect: Z=2.72(P=0.01)  
MCPI with biofeedback 10050-100 -50 0 no-treatment control
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Analysis 5.3.   Comparison 5 Multi-component psychological intervention (with biofeedback) versus no-
treatment control, Outcome 3 Symptom Improvement (measured by CPSR) - Sensitivity Analysis Strategy 1.




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 45.2 (60) 10 9.5 (53.3) 16.53% 35.7[-14.05,85.45]
Blanchard 1992b 38 27.6 (61.7) 39 6.4 (56.3) 58.69% 21.21[-5.19,47.61]
NeF 1987 10 50.4 (47.2) 10 15.4 (45.5) 24.78% 35[-5.62,75.62]
   
Total *** 58   59   100% 27.02[6.8,47.24]
Heterogeneity: Tau2=0; Chi2=0.45, df=2(P=0.8); I2=0%  
Test for overall effect: Z=2.62(P=0.01)  
MCPI with biofeedback 10050-100 -50 0 no-treatment control
 
 
Analysis 5.4.   Comparison 5 Multi-component psychological intervention (with biofeedback) versus no-
treatment control, Outcome 4 Symptom Improvement (measured by CPSR) - Sensitivity Analysis Strategy 2.




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 45.2 (60) 10 9.5 (53.3) 16.53% 35.7[-14.05,85.45]
Blanchard 1992b 38 32.4 (61.7) 39 8.3 (56.3) 58.69% 24.15[-2.25,50.55]
NeF 1987 10 50.4 (47.2) 10 15.4 (45.5) 24.78% 35[-5.62,75.62]
   
Total *** 58   59   100% 28.75[8.52,48.97]
Heterogeneity: Tau2=0; Chi2=0.28, df=2(P=0.87); I2=0%  
Test for overall effect: Z=2.79(P=0.01)  
MCPI with biofeedback 10050-100 -50 0 no-treatment control
 
 
Analysis 5.5.   Comparison 5 Multi-component psychological intervention (with biofeedback) versus no-
treatment control, Outcome 5 Symptom Improvement (measured by CPSR) - Sensitivity Analysis Strategy 3.




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 45.2 (60) 10 9.5 (53.3) 16.53% 35.7[-14.05,85.45]
Blanchard 1992b 38 27.6 (61.7) 39 8.3 (56.3) 58.69% 19.36[-7.04,45.76]
NeF 1987 10 50.4 (47.2) 10 15.4 (45.5) 24.78% 35[-5.62,75.62]
   
Total *** 58   59   100% 25.94[5.71,46.16]
Heterogeneity: Tau2=0; Chi2=0.58, df=2(P=0.75); I2=0%  
Test for overall effect: Z=2.51(P=0.01)  
MCPI with biofeedback 10050-100 -50 0 no-treatment control
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Analysis 5.6.   Comparison 5 Multi-component psychological intervention (with biofeedback) versus no-
treatment control, Outcome 6 Symptom Improvement (measured by CPSR) - Sensitivity Analysis Strategy 4.




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 45.2 (60) 10 9.5 (53.3) 16.53% 35.7[-14.05,85.45]
Blanchard 1992b 38 27.6 (61.7) 39 15.4 (56.3) 58.69% 12.18[-14.22,38.58]
NeF 1987 10 50.4 (47.2) 10 18.9 (45.5) 24.78% 31.5[-9.12,72.12]
   
Total *** 58   59   100% 20.85[0.63,41.08]
Heterogeneity: Tau2=0; Chi2=1.02, df=2(P=0.6); I2=0%  
Test for overall effect: Z=2.02(P=0.04)  
MCPI with biofeedback 10050-100 -50 0 no-treatment control
 
 
Analysis 5.7.   Comparison 5 Multi-component psychological intervention (with
biofeedback) versus no-treatment control, Outcome 7 Clinical Response (complete case).




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Blanchard 1992a 6/10 2/10 15.32% 3[0.79,11.44]
Blanchard 1992b 16/31 10/31 76.61% 1.6[0.87,2.96]
NeF 1987 6/10 1/9 8.06% 5.4[0.79,36.68]
   
Total (95% CI) 51 50 100% 2.12[1.24,3.62]
Total events: 28 (MCPI with biofeedback), 13 (no-treatment control)  
Heterogeneity: Tau2=0; Chi2=1.98, df=2(P=0.37); I2=0%  
Test for overall effect: Z=2.75(P=0.01)  
MCPI with biofeedback 1000.01 100.1 1 no-treatment control
 
 
Analysis 5.8.   Comparison 5 Multi-component psychological intervention (with biofeedback)
versus no-treatment control, Outcome 8 Clinical Response - Sensitivity Analysis - Random E:ects.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Blanchard 1992a 6/10 2/10 16% 3[0.79,11.44]
Blanchard 1992b 16/31 10/31 76.19% 1.6[0.87,2.96]
NeF 1987 6/10 1/9 7.81% 5.4[0.79,36.68]
   
Total (95% CI) 51 50 100% 1.95[1.14,3.32]
Total events: 28 (MCPI with biofeedback), 13 (no-treatment control)  
Heterogeneity: Tau2=0; Chi2=1.98, df=2(P=0.37); I2=0%  
Test for overall effect: Z=2.44(P=0.01)  
MCPI with biofeedback 1000.01 100.1 1 no-treatment control
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Analysis 5.9.   Comparison 5 Multi-component psychological intervention (with biofeedback) versus no-
treatment control, Outcome 9 Clinical Response -Sensitivity Analysis - Missing Outcome Data - 1.5:1.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Blanchard 1992a 6/10 2/10 12.63% 3[0.79,11.44]
Blanchard 1992b 18/38 13/39 81.05% 1.42[0.81,2.48]
NeF 1987 6/10 1/10 6.32% 6[0.87,41.21]
   
Total (95% CI) 58 59 100% 1.91[1.17,3.13]
Total events: 30 (MCPI with biofeedback), 16 (no-treatment control)  
Heterogeneity: Tau2=0; Chi2=2.88, df=2(P=0.24); I2=30.5%  
Test for overall effect: Z=2.57(P=0.01)  
MCPI with biofeedback 1000.01 100.1 1 no-treatment control
 
 
Analysis 5.10.   Comparison 5 Multi-component psychological intervention (with biofeedback) versus
no-treatment control, Outcome 10 Clinical Response -Sensitivity Analysis - Missing Outcome Data - 2:1.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Blanchard 1992a 6/10 2/10 12.63% 3[0.79,11.44]
Blanchard 1992b 16/38 13/39 81.05% 1.26[0.71,2.26]
NeF 1987 6/10 1/10 6.32% 6[0.87,41.21]
   
Total (95% CI) 58 59 100% 1.78[1.08,2.95]
Total events: 28 (MCPI with biofeedback), 16 (no-treatment control)  
Heterogeneity: Tau2=0; Chi2=3.46, df=2(P=0.18); I2=42.19%  
Test for overall effect: Z=2.24(P=0.02)  
MCPI with biofeedback 1000.01 100.1 1 no-treatment control
 
 
Analysis 5.11.   Comparison 5 Multi-component psychological intervention
(with biofeedback) versus no-treatment control, Outcome 11 Abdominal Pain.




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 9.7 (7) 10 9.1 (10.6) 60.84% 0.6[-7.27,8.47]
Blanchard 1992b 31 17.5 (19) 31 22 (20.4) 39.16% -4.5[-14.31,5.31]
   
Total *** 41   41   100% -1.4[-7.54,4.74]
Heterogeneity: Tau2=0; Chi2=0.63, df=1(P=0.43); I2=0%  
Test for overall effect: Z=0.45(P=0.66)  
MCPI with biofeedback 10050-100 -50 0 no-treatment control
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Analysis 5.12.   Comparison 5 Multi-component psychological intervention
(with biofeedback) versus no-treatment control, Outcome 12 Depression.




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 8.4 (5.3) 10 11.7 (10.9) 17.09% -3.3[-10.81,4.21]
Blanchard 1992b 31 6.6 (6.7) 31 10.5 (7) 82.91% -3.9[-7.31,-0.49]
   
Total *** 41   41   100% -3.8[-6.9,-0.69]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=2.4(P=0.02)  
MCPI with biofeedback 10050-100 -50 0 no-treatment control
 
 
Analysis 5.13.   Comparison 5 Multi-component psychological intervention
(with biofeedback) versus no-treatment control, Outcome 13 Anxiety - State.




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 33.3 (10.3) 10 42.2 (18.6) 8.54% -8.9[-22.08,4.28]
Blanchard 1992b 31 35.9 (9.2) 31 44.5 (6.8) 91.46% -8.6[-12.63,-4.57]
   
Total *** 41   41   100% -8.63[-12.48,-4.77]
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%  
Test for overall effect: Z=4.39(P<0.0001)  
MCPI with biofeedback 10050-100 -50 0 no-treatment control
 
 
Analysis 5.14.   Comparison 5 Multi-component psychological intervention
(with biofeedback) versus no-treatment control, Outcome 14 Anxiety - Trait.




Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 37.9 (7.6) 10 48.5 (14) 16.23% -10.6[-20.47,-0.73]
Blanchard 1992b 31 43.8 (9.4) 31 46.5 (8) 83.77% -2.7[-7.05,1.65]
   
Total *** 41   41   100% -3.98[-7.96,-0]
Heterogeneity: Tau2=0; Chi2=2.06, df=1(P=0.15); I2=51.46%  
Test for overall effect: Z=1.96(P=0.05)  
MCPI with biofeedback 10050-100 -50 0 no-treatment control
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Comparison 6.   Multi-component psychological intervention (with biofeedback) versus attention control





Statistical method Effect size
1 Symptom Improvement (mea-
sured by CPSR)
2 80 Mean Difference (IV, Fixed, 95% CI) 4.02 [-21.41, 29.45]
2 Clinical Response (complete
case)
2 80 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.72, 1.69]
3 Abdominal Pain 2 80 Mean Difference (IV, Fixed, 95% CI) 0.72 [-5.40, 6.84]
4 Depression 2 80 Mean Difference (IV, Fixed, 95% CI) 0.13 [-2.73, 2.98]
5 Anxiety - State 2 80 Mean Difference (IV, Fixed, 95% CI) -0.74 [-5.38, 3.89]
6 Anxiety - Trait 2 80 Mean Difference (IV, Fixed, 95% CI) 2.05 [-2.48, 6.57]
 
 
Analysis 6.1.   Comparison 6 Multi-component psychological intervention (with biofeedback)
versus attention control, Outcome 1 Symptom Improvement (measured by CPSR).
Study or subgroup MCPI with
biofeedback
Attention control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 45.2 (59.3) 9 38 (31.6) 36.38% 7.2[-34.96,49.36]
Blanchard 1992b 31 32.4 (63.2) 30 30.2 (63.8) 63.62% 2.2[-29.68,34.08]
   
Total *** 41   39   100% 4.02[-21.41,29.45]
Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.85); I2=0%  
Test for overall effect: Z=0.31(P=0.76)  
MCPI with biofeedback 10050-100 -50 0 Attention control
 
 
Analysis 6.2.   Comparison 6 Multi-component psychological intervention (with
biofeedback) versus attention control, Outcome 2 Clinical Response (complete case).




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Blanchard 1992a 6/10 5/9 27% 1.08[0.5,2.34]
Blanchard 1992b 16/31 14/30 73% 1.11[0.66,1.85]
   
Total (95% CI) 41 39 100% 1.1[0.72,1.69]
Total events: 22 (MCPI with biofeedback), 19 (Attention control)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.96); I2=0%  
Test for overall effect: Z=0.43(P=0.67)  
MCPI with biofeedback 1000.01 100.1 1 Attention control
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Analysis 6.3.   Comparison 6 Multi-component psychological intervention
(with biofeedback) versus attention control, Outcome 3 Abdominal Pain.
Study or subgroup MCPI with
biofeedback
Attention control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 9.7 (7) 9 11.7 (10.8) 54.63% -2[-10.28,6.28]
Blanchard 1992b 31 17.5 (19) 30 13.5 (17.2) 45.37% 4[-5.09,13.09]
   
Total *** 41   39   100% 0.72[-5.4,6.84]
Heterogeneity: Tau2=0; Chi2=0.91, df=1(P=0.34); I2=0%  
Test for overall effect: Z=0.23(P=0.82)  
MCPI with biofeedback 10050-100 -50 0 Attention control
 
 
Analysis 6.4.   Comparison 6 Multi-component psychological intervention
(with biofeedback) versus attention control, Outcome 4 Depression.
Study or subgroup MCPI with
biofeedback
Attention control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 8.4 (5.3) 9 7.9 (5) 38% 0.5[-4.13,5.13]
Blanchard 1992b 31 6.6 (6.7) 30 6.7 (7.7) 62% -0.1[-3.73,3.53]
   
Total *** 41   39   100% 0.13[-2.73,2.98]
Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.84); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
MCPI with biofeedback 10050-100 -50 0 Attention control
 
 
Analysis 6.5.   Comparison 6 Multi-component psychological intervention
(with biofeedback) versus attention control, Outcome 5 Anxiety - State.
Study or subgroup MCPI with
biofeedback
Attention control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 33.3 (10.3) 9 36.3 (14.5) 16.45% -3[-14.42,8.42]
Blanchard 1992b 31 35.9 (9.2) 30 36.2 (10.9) 83.55% -0.3[-5.37,4.77]
   
Total *** 41   39   100% -0.74[-5.38,3.89]
Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%  
Test for overall effect: Z=0.31(P=0.75)  
MCPI with biofeedback 10050-100 -50 0 Attention control
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Analysis 6.6.   Comparison 6 Multi-component psychological intervention
(with biofeedback) versus attention control, Outcome 6 Anxiety - Trait.
Study or subgroup MCPI with
biofeedback
Attention control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Blanchard 1992a 10 37.9 (7.6) 9 40.8 (10.3) 30.34% -2.9[-11.11,5.31]
Blanchard 1992b 31 43.8 (9.4) 30 39.6 (12) 69.66% 4.2[-1.22,9.62]
   
Total *** 41   39   100% 2.05[-2.48,6.57]
Heterogeneity: Tau2=0; Chi2=2, df=1(P=0.16); I2=49.98%  
Test for overall effect: Z=0.89(P=0.38)  
MCPI with biofeedback 10050-100 -50 0 Attention control
 
 
Comparison 7.   Biofeedback versus relaxation control







Statistical method Effect size
1 Symptom severity 1 10 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Stool frequency 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Abdominal pain 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Depression 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Anxiety 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 7.1.   Comparison 7 Biofeedback versus relaxation control, Outcome 1 Symptom severity.
Study or subgroup Biofeedback Relaxation Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
DeRoo 1988 5 2.8 (0) 5 2.5 (0)   Not estimable
   
Total *** 5   5   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Biofeedback 10050-100 -50 0 Relaxation
 
 
A P P E N D I C E S
Appendix 1. Database search strategies
MEDLINE
#1 Irritable bowel syndrome[mh]
#2 Colonic Diseases, Functional[mh]
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#3 “irritable bowel syndrome”[tw]
#4 irritable bowel syndrome*[tw]
#5 IBS[tw]
#6 “functional abdominal pain”[tw]
#7 “functional gastrointestinal disorders”[tw]

















#25 #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24
#26 #13 AND #25
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#51 “gut directed hypnotherapy”[tw]
#52 “relaxation training”[tw]






#59 heart rate vari*[tw]
#60 HRV
#61 #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45
OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60
#62 randomized controlled trial [pt]
#63 controlled clinical trial [pt]
#64 randomized [tiab]
#65 placebo [tiab]




#70 #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69
#71 animals [mh]
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#72 humans [mh]
#73 #71 AND #72
#74 #71 NOT #73
#75 #27 AND #61 AND #70
#76 #75 NOT #74
Cochrane Central Register of Controlled Trials (CENTRAL)
#1 MeSH descriptor: [Irritable Bowel Syndrome] explode all trees
#2 MeSH descriptor: [Colonic Diseases, Functional] explode all trees
#3 "irritable bowel syndrome":ti,ab,kw (Word variations have been searched)
#4 irritable bowel syndrome*:ti,ab,kw (Word variations have been searched)
#5 IBS:ti,ab,kw (Word variations have been searched)
#6 "functional abdominal pain":ti,ab,kw (Word variations have been searched)
#7 "functional gastrointestinal disorders":ti,ab,kw (Word variations have been searched)
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 recurrent:ti,ab,kw (Word variations have been searched)
#10 chronic:ti,ab,kw (Word variations have been searched)
#11 excessive:ti,ab,kw (Word variations have been searched)
#12 hypersensitivity:ti,ab,kw (Word variations have been searched)
#13 #9 or #10 or #11 or #12
#14 diarrhea*:ti,ab,kw (Word variations have been searched)
#15 diarrhoe*:ti,ab,kw (Word variations have been searched)
#16 diarhe*:ti,ab,kw (Word variations have been searched)
#17 diarhoe*:ti,ab,kw (Word variations have been searched)
#18 "gastro enteritis":ti,ab,kw (Word variations have been searched)
#19 "abdominal pain":ti,ab,kw (Word variations have been searched)
#20 abdominal cramp*:ti,ab,kw (Word variations have been searched)
#21 bloating:ti,ab,kw (Word variations have been searched)
#22 "disturbed defecation":ti,ab,kw (Word variations have been searched)
#23 constipat*:ti,ab,kw (Word variations have been searched)
#24 flatulen*:ti,ab,kw (Word variations have been searched)
#25 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24
#26 #13 and #25
#27 #8 or #26
#28 MeSH descriptor: [Biofeedback, Psychology] explode all trees
#29 MeSH descriptor: [Neurofeedback] explode all trees
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#30 MeSH descriptor: [Electroencephalography] explode all trees
#31 MeSH descriptor: [Electromyography] explode all trees
#32 MeSH descriptor: [Monitoring, Physiologic] explode all trees
#33 MeSH descriptor: [Thermography] explode all trees
#34 MeSH descriptor: [Hypnosis] explode all trees
#35 MeSH descriptor: [Relaxation Therapy] explode all trees
#36 MeSH descriptor: [Yoga] explode all trees
#37 MeSH descriptor: [Mindfulness] explode all trees
#38 MeSH descriptor: [Meditation] explode all trees
#39 biofeed*:ti,ab,kw (Word variations have been searched)
#40 myofeedback:ti,ab,kw (Word variations have been searched)
#41 neurobiofeedback:ti,ab,kw (Word variations have been searched)
#42 neurofeed*:ti,ab,kw (Word variations have been searched)
#43 neurotherap*:ti,ab,kw (Word variations have been searched)
#44 electroencephalograp*:ti,ab,kw (Word variations have been searched)
#45 EEG:ti,ab,kw (Word variations have been searched)
#46 electromyograph*:ti,ab,kw (Word variations have been searched)
#47 EMG:ti,ab,kw (Word variations have been searched)
#48 thermistor*:ti,ab,kw (Word variations have been searched)
#49 hypnosis:ti,ab,kw (Word variations have been searched)
#50 hypnotherap*:ti,ab,kw (Word variations have been searched)
#51 "gut directed hypnotherapy":ti,ab,kw (Word variations have been searched)
#52 "relaxation training":ti,ab,kw (Word variations have been searched)
#53 "progressive muscle relaxation":ti,ab,kw (Word variations have been searched)
#54 "progressive relaxation":ti,ab,kw (Word variations have been searched)
#55 yoga*:ti,ab,kw (Word variations have been searched)
#56 mindful*:ti,ab,kw (Word variations have been searched)
#57 meditati*:ti,ab,kw (Word variations have been searched)
#58 EmWAVE:ti,ab,kw (Word variations have been searched)
#59 heart rate vari*:ti,ab,kw (Word variations have been searched)
#60 HRV:ti,ab,kw (Word variations have been searched)
#61 #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47
or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60
#62 MeSH descriptor: [Animals] explode all trees
#63 MeSH descriptor: [Humans] explode all trees
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#64 #62 and #63
#65 #62 not #64
#66 #27 and #61
#67 #66 not #65
Embase
#1 (‘intestine function disorder’/exp OR ‘irritable colon‘ OR ‘irritable bowel syndrome*’ OR IBS OR ‘functional gastrointestinal disorder*’
OR ‘functional abdominal pain’)
#2 (recurrent OR chronic OR excessive OR hypersensitivity) AND ('diarrhea'/exp OR 'gastroenteritis'/exp OR 'abdominal cramp'/exp OR
'abdominal pain'/exp OR 'bloating'/exp OR 'constipation'/exp OR 'flatulence'/exp OR ‘diarrhea*’ OR ‘diarrhoe*’ OR ‘diarhe*’ OR ‘diarhoe*’
OR ‘gastro enteritis’ OR ‘abdominal cramp*’ OR ‘abdominal pain*’ OR bloating OR ‘constipat*’ OR ‘flatulen*’ OR ‘disturbed defecation’)
#3 1 OR 2
#4 ('feedback system'/exp OR 'neurofeedback'/exp OR 'electroencephalography'/exp OR 'electromyography'/exp OR 'physiologic
monitoring'/exp OR 'thermography'/exp OR 'thermistor'/exp OR 'hypnosis'/exp OR 'relaxation training'/exp OR 'yoga'/exp OR
'mindfulness'/exp OR 'meditation'/exp OR ‘feedback system’ OR 'biofeed*' OR 'neurofeed*' OR myofeedback OR neurobiofeedback OR
'neurotherap*' OR 'electroencephalograp*' OR EEG OR 'electromyograph*' OR EMG OR thermistor OR hypnosis OR 'hypnotherap*' OR 'gut
directed hypnotherapy' OR 'relaxation therap*' OR 'relaxation training' OR 'progressive muscle relaxation' OR 'progressive relaxation' OR
'yoga*' OR 'mindful*' OR 'meditati*' OR EmWAVE OR 'heart rate vari*' OR HRV)
#5 (random:ti,ab OR placebo:ti,ab OR double-blind:ti,ab)
#6 3 AND 4 AND 5
CINAHL Complete
((MH “Irritable bowel syndrome+”) OR (MH “Colonic Diseases, Functional+”) OR “irritable bowel syndrome” OR Irritable bowel syndrome*
OR IBS OR “Functional abdominal pain” OR “functional gastrointestinal disorder*”) OR ((recurrent OR chronic OR excessive OR
hypersensitivity) AND (diarrhea* OR diarrhoe* OR diarhe* OR diarhoe* OR “gastro enteritis” OR "abdominal pain" OR abdominal cramp*
OR bloating OR "disturbed defecation" OR constipat* OR flatulen*))
AND
((MH “Biofeedback, Psychology+”) OR (MH “Neurofeedback+”) OR (MH “Electroencephalography+”) OR (MH “Electromyography+”) OR
(MH “Monitoring, Physiologic+”) OR (MH “Thermography+”) OR (MH “Hypnosis+”) OR (MH “Relaxation Therapy+”) OR (MH “Yoga+”)
OR (MH “Mindfulness+”) OR (MH “Meditation+”) OR biofeed* OR myofeedback OR neurobiofeedback OR neurofeed* OR neurotherap*
OR electroencephalograp* OR EEG OR electromyograph* OR EMG OR thermistor* OR hypnosis OR hypnotherap* OR “gut directed
hypnotherapy” OR “relaxation training” OR "progressive muscle relaxation" OR “progressive relaxation” OR yoga* OR mindful* OR
meditati* OR EmWAVE OR heart rate vari* OR HRV))
AND
((PT “randomized controlled trial”) OR (PT “clinical trial”) OR (AB “randomized”) OR (TI “randomized”) OR (AB “trial*”) OR (TI “trial*”) OR
(AB “placebo”) OR (TI “placebo”) OR (AB “randomly”) OR (TI “randomly”) OR (AB “trial”) OR (TI “trial”) OR (AB “groups”) OR (TI “groups”))
NOT
((MH "animals+") NOT (MH "humans+"))
The Allied and Complementary Medicine Database (AMED)
#1"Irritable bowel syndrome"
#2 Colonic Diseases, Functional
#3 irritable bowel syndrome*
#4 IBS
#5 “Functional abdominal pain”
#6 “functional gastrointestinal disorders”
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#44 hypnotherap*
#45 “gut directed hypnotherapy”
#46 “relaxation training”
#47 "progressive muscle relaxation"
#48 “progressive relaxation”
#49 EmWAVE
#50 heart rate vari*
#51 HRV
#52 #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44
OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51
#53 #26 AND #52
Appendix 2. Assessment of heterogeneity
We planned to follow the proposed 13 recommendations for assessing and investigating clinical heterogeneity in systematic reviews
(Gagnier 2013). While not all were relevant due to limited identified studies, we describe below how we had planned to apply these
recommendations in our review.
1. Review team: we have built a team with both clinical experience in biofeedback and irritable bowel syndrome (IBS), as well as
methodological experience in randomized controlled trial (RCT) design, systematic reviews, and meta-analyses.
2. Planning
a. Our a priori variables to consider in clinical heterogeneity investigation included: type of biofeedback (e.g. heart rate variability),
subtype of IBS (i.e. IBS constipation predominant [IBS-C], diarrhea predominant [IBS-D], or mixed [IBS-M]), and diagnostic criteria
(e.g. Manning, Rome I-IV).
b. Any post hoc investigations were to be driven by visual inspection of forest plots.
c. Investigations were to utilize subgroup analysis or meta-regression as appropriate, subjected to the proposed checklist of subgroup
believability (Sun 2012).
d. Heterogeneity exploration was to be viewed as hypothesis generating.
3. Rationale: our rationale for our a priori variable choice of biofeedback type, IBS subtype, and diagnostic criteria follow our clinical
experience as well as recent research suggesting diFering mechanisms for IBS-C and IBS-D (Kim 2017). Ad hoc variable choices were
to follow pathology, clinical evidence or clinical experience. All variables were to be subject to the proposed checklist of subgroup
believability (Sun 2012).
4. Types of variables: all variables used were to be based on the patient, intervention, outcome, or 'other' level as described by Gagnier
2013.
5. Role of statistical heterogeneity: statistical tests such as the Chi2 and I2 statistics were to be utilized to help explore heterogeneity but
formal statistical tests would not dictate heterogeneity investigation for numerous reasons, including that they are oMen underpowered
as per the recommendations of the heterogeneity Delphi group (Gagnier 2013).
6. Plotting and visual aids: we were to use forest plots as a visual aid in investigating heterogeneity.
7. Dealing with outliers: in the case of clear outliers we were to conduct a sensitivity analysis by removing the outlier trial and comparing
the new meta-analytic result to the result before removal.
8. Number of investigations to explore: we followed the principle of parsimony in our variable exploration. We have chosen only three a
priori variables.
9. Individual versus aggregate data: this review will utilize aggregate level data only, with the recognition that this approach is liable to
ecological bias for patient-level variables. If appropriate these limitations were to be discussed in our discussion.
10.Evidence synthesis: in the case that trials are not reasonably combinable, we were to utilize a narrative synthesis (Popay 2006). We did
not pool mixed modality intervention trials (i.e. biofeedback plus A versus control) together with biofeedback alone intervention trials
(i.e. biofeedback versus control). We did not combine trials which utilize diFering control types (e.g. active, no treatment, and sham).
11.Statistical methods: subgroup analyses were to be utilized as appropriate using RevMan and tests of interaction by the review team.
If meta-regression was called for, we were to utilize R based statistical packages and consult with a statistician familiar with this
methodology.
12.Interpretation of findings: we were to view our heterogeneity investigations as hypothesis generating, express our confidence in the
validity of the findings, and suggest specifically how future research could benefit the evidence base.
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13.Reporting:
a. we attempted to contact study authors for unreported data on the heterogeneity variables we are exploring (e.g. IBS subtype).
b. we were to report all variables used for heterogeneity exploration.
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